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Abstract 
The cytochrome P450-2C19 enzyme is involved in the metabolism of about 10 % of 
all drugs used today and displays high genetic polymorphism, causing absent, 
decreased or elevated enzyme activity that divides the population into different 
metabolic phenotypes. CYP2C19 enzymatic activity is also highly influenced by 
different substances including drugs and in vivo studies have shown that estradiol 
and 17α-ethinylestradiol, commonly used in hormone replacement therapy and oral 
contraceptives, decreased CYP2C19 mediated metabolism in vivo in humans. We 
investigated by which mechanisms this inhibition is mediated and found that the 
estrogens at rather high concentrations competitively inhibit CYP2C19 activity, but 
more importantly, at low clinically relevant concentrations caused a decreased gene 
transcription through a novel estrogen responsive element half-site in the CYP2C19 
promoter region. Such estrogen CYP2C19 interactions are important to consider 
during drug development. 
Recently is was described by our laboratory that subjects lacking functional 
CYP2C19 enzyme had lower depressive symptoms based on analyses of a large twin 
cohort. To investigate CYP2C19’s potential effect on behavior and brain function a 
transgenic mouse model expressing the human CYP2C19 gene was characterized. 
We found that CYP2C19 is expressed in the developing fetal but not in adult brain. 
Newborn pups homozygous for the CYP2C19 gene insert display high neonatal 
lethality and severe brain malformations with complete commissural agenesis and a 
severely reduced hippocampus. Hemizygous mice (CYP2C19Tg-Hem) showed less 
extensive phenotypes, thus survived and were characterized at 7 (adolescent) and 15 
weeks (young adult) of age. CYP2C19Tg-Hem mice display increased stress 
sensitivity and anxiety-like behavior, which was more pronounced in young adult 
mice. Furthermore, a smaller hippocampal formation was seen at both ages as 
measured by manual outlining of brain sections and confirmed in adult mice by 
magnetic resonance imaging. The CYP2C19Tg-Hem mice hippocampal formation 
furthermore displayed an increased neuronal activation, or c-fos expression, after 
acute stress. This might be explained by the drastic reduction of immature neurons 
and the reduced number of GABAergic interneurons observed in the dentate gyrus of 
the hippocampus in the CYP2C19 transgenic mice.   
The results indicate that CYP2C19 expression during brain development increases 
the susceptibility to develop anxiety-related disorders later in life. This is interesting 
since, as mentioned above, absence of CYP2C19 enzyme is protective against 
depressive symptoms in humans, a phenotype displaying high comorbidity with 
anxiety disorders. Since the pathophysiology behind major depressive disorder and 
anxiety disorders is still mostly unknown, the model presented could be used for the 
investigation of factors important in the pathogenesis of these disorders and might 
also be used in the development of novel anxiolytic drugs.  
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1 │ Introduction 
1.1 │ Cytochrome P450 enzymes 
Cytochrome P450s (CYPs) constitute a large family of important phase I enzymes 
involved in the oxidative activation or deactivation of both endogenous and exogenous 
substances.1,2 Besides their important functions in the metabolism of e.g. toxins and 
pharmaceuticals, CYPs have an essential part in endogenous metabolic functions such 
as cholesterol, fatty acid, and vitamin metabolism.3 CYP enzymes are most abundant in 
the liver, where they are membrane-bound and localized mainly in the endoplasmic 
reticulum whereas some forms are found in the mitochondria. CYPs are heme-proteins 
and function mainly as monoxygenases, transferring one oxygen atom from molecular 
oxygen to a substrate.4 Apart from being highly expressed in the liver, significant 
expression can also be found in extrahepatic tissues such as lung, gastrointestinal tract, 
and adrenal gland.2,5  
 
CYP nomenclature is based on amino acid homology with enzymes being divided into 
different families (>40 % homology, e.g. CYP2), subfamilies (>55 %, e.g. CYP2C), and 
individual enzymes (e.g. CYP2C19).2,4 For further reading see the CYP allele 
nomenclature database (http://www.cypalleles.ki.se).6 In humans, CYP family 1-3 are 
responsible for approximately 80 % of all phase I drug metabolism.1,7,8  
 
CYPs are, as the majority of both phase I and phase II drug metabolizing enzymes, 
highly polymorphic. This polymorphism has in many cases been connected to high 
interindividual differences in drug response and can lead to adverse drug reactions and 
loss of efficacy of drugs.1,9 Furthermore, the functional consequences of the different 
alleles differ and there are large differences in allele frequencies between ethnic 
groups.10 Based on this polymorphism the population can be divided into different 
metabolic phenotypes. Poor metabolizers (PMs) are defined by a complete lack of 
enzyme function, whereas intermediate metabolizers (IMs) are carriers of one functional 
and one nonfunctional allele. The wildtype allele is usually denominated *1 in CYP 
nomenclature and extensive metabolizers (EMs) are homozygous for this allelic variant. 
Some CYP alleles display increased transcription11 or multiple copies12 thus generating 
a ultrarapid metabolizer (UM) phenotype.8 Besides the genetic variants other factors 
such as age,13,14 gender,15 environmental factors, and drug interactions highly affect 
CYP expression and activity.1  
1.1.2 │ CYPs in the brain 
Besides being mainly expressed in the liver, and to a lesser extent in the gastrointestinal 
tract and other extrahepatic tissues, a limited number of CYPs are also found within the 
central nervous system (CNS). Many drugs with effects in the CNS are metabolized by 
CYPs16,17 and there is a pronounced interindividual variation in the response to these 
substances that is not always related to the drug plasma levels. Numerous studies have 
investigated CYP expression in the rodent brain, however only a limited number of 
CYPs expressed in brain have been detected in humans.17,18 It is suggested that most of 
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the brain-expressed CYPs predominantly have endogenous effects in e.g. steroid 
metabolism; nonetheless locally expressed CYPs could be crucial for the individual 
response to centrally acting drugs due to polymorphism and induction. Although the 
overall brain content of cytochrome P450 enzymes is relatively low, these enzymes 
display great regional and cell specificity that can lead to rather high levels in specific 
cells.19 
1.1.3 │ Human CYP2D6 and brain function 
Some CYPs traditionally categorized as drug metabolizing enzymes have during the last 
decade been implicated also to contribute in the biotransformation of endogenous 
compounds. One enzyme extensively studied with regards to this is CYP2D6.20 
CYP2D6 is an important drug metabolizing enzyme, involved in the metabolism of 20 
% of all drugs8 and around 50 % of all centrally acting drugs on the market17 such as 
antidepressants, antipsychotics and opioids.21 CYP2D6 also displays genetic 
polymorphism creating metabolic phenotypes ranging from PM to UM with multiple 
gene copies.12  
 
CYP2D6 mRNA and protein has been detected in several human brain areas22 and it 
was recently revealed that brain CYP2D6-mediated metabolism alter codeine-induced 
analgesia in rats.23 CYP2D6 is suggested to be involved in the endogenous metabolism 
of transmitter precursors into serotonin and dopamine.24,25 Besides the production of 
neurotransmitters CYP2D6 is possibly also involved in the 21-hydroxylation of 
progesterone26 and in the metabolism of the endogenous cannabinoid anandamide.27 
These endogenous substrates for CYP2D6 might be the reasons for the many 
associations of polymorphism in the CYP2D6 gene with several personality traits and 
neurological conditions. As reviewed by Cheng et al. (2013)28 PMs are in some cohorts 
significantly associated with an anxious personality trait and are less successful in 
socialization than EMs.28,29 However, not all studies find consistent correlations 
between CYP2D6 polymorphism and personality traits.30 The UM phenotype has on the 
other hand been suggested to be associated with higher suicidal risk31,32 and increased 
suicidal behavior.33 CYP2D6 PMs have additionally been shown to exhibit higher brain 
perfusion rates in the thalamus and the right hippocampus in healthy subjects, further 
suggesting an endogenous function of CYP2D6 in the human brain.21 CYP2D6 function 
in the brain is still not well understood but the hypothesis regarding a possible 
endogenous role for this enzyme and its effects on brain function has served as 
inspiration for this thesis work. 
1.2 │ CYP2C19 
The human CYP2C subfamily contains 4 highly homologous genes, CYP2C8, -2C9, -
2C18, and -2C19, clustered together on chromosome 10 (10q24). In this thesis the focus 
has been on CYP2C19, one of the major drug metabolizing enzymes in humans 
responsible for approximately 7-10 % of all hepatic phase I drug metabolism.8,34 The 
CYP2C19 gene contains nine exons encoding a 490 amino-acid protein. CYP2C19 is 
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mainly expressed in the liver but some expression has also been found in the small 
intestine.35-37  
1.2.1 │ CYP2C19 and drug metabolism 
The importance of CYP2C19 in drug metabolism is widely known and intensively 
studied, especially with regards to the polymorphic nature of the gene. CYP2C19 is 
involved in the metabolism of approximately 7-10 % of all clinically used drugs on the 
market today displaying broad substrate specificity.8,34 Substrates for CYP2C19 include 
several proton-pump inhibitors with omeprazole being the most well-known and studied 
substrate. The formation of the metabolite 5-hydroxyomeprazole from the R-enantiomer 
(R-omeprazole) is highly specific and extensively used for measuring CYP2C19 
enzyme activity.38-40 CYP2C19 is furthermore involved in the metabolism of several 
different psychotropic drugs including selective serotonin reuptake inhibitors (SSRIs) 
e.g. sertraline41,42 and citalopram,43,44 tricyclic antidepressants (TCAs) like 
amitriptyline45 and clomipramine,46 and the monoaminoxidase (MAO) inhibitor 
moclobemide.47 Other psychotropic substrates include benzodiazepines e.g. diazepam48 
and the anticonvulsant drug mephenytoin. CYP2C19 metabolic phenotypes (see 1.1.3) 
can be characterized by using racemic mephenytoin and measuring the urine R/S ratio 
since CYP2C19 specifically metabolizes S-mephenytoin.39,49,50 CYP2C19 also 
participates in the activation of the antimalarial drug proguanil51 and the antiplatelet 
drug clopidogrel.52 CYP2C19 is involved in the metabolism of many additional drugs, 
however with a minor role due to the main contribution of other drug metabolizing 
enzymes.  
1.2.2 │ Polymorphism in the CYP2C19 gene 
Like many other CYPs CYP2C19 is highly polymorphic with both common and rare 
allelic variants leading to everything from absent to high enzyme activity with great 
differences in allelic frequencies between populations. There are more than 30 different 
allelic variants of CYP2C19 characterized today and depending on the allelic variants 
individuals can be classified into metabolic phenotypes.1,10 
  
Eight different allelic variants (CYP2C19*2 to CYP2C19*8) encode a nonfunctional 
CYP2C19 enzyme, with the CYP2C19*2 and the CYP2C19*3 null alleles displaying the 
highest frequencies. The allele frequency of the null alleles varies between 12 and 23 % 
in Asians compared to 1-6 % in Caucasian populations. In contrast, the PM phenotype 
does not seem to exist in the Cuna Indians of Panama whereas 79 % of the population 
on the island of Vanuatu in the Pacific Ocean displays this phenotype (reviewed by 
Desta et al.).53 
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Table 1 │ Overview of selected CYP2C19 substrates 
 
*Also used in hormone replacement therapy. 
 
CYP2C19*2 is the most common defective allele and is defined by a point mutation 
(G681A) leading to a premature termination of protein synthesis. The allele frequencies 
of the CYP2C19*2 allele ranges from 15 % in Caucasians to 17 % and 30 % in African-
Americans and Chinese, respectively.53 The CYP2C19*3 variant is defined by a single 
base transition (G636A) that results in a truncated protein and contributes to the PM 
phenotype mainly in Asian populations with the allelic frequency of around 10-12 % in 
Japanese and Korean subjects,54,55 compared to being almost nonexistent in 
Caucasians.56 
 
The CYP2C19*17 allele represents a rapid metabolizer (RM) phenotype and is defined 
by two linked single nucleotide polymorphisms (SNPs) in the CYP2C19 gene promoter 
region. The SNPs are located in the 5’-flanking region at -806(C>T) and -3402(C>T) 
relative to translation start and the -806 SNP introduces a novel transcription factor 
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binding site that causes increased gene transcription.11 The allele frequency of 
CYP2C19*17 is around 18 % in Swedes but ranges between 18 and 27 % in different 
European populations.11,57,58 The variant is rarer in Asian populations with an allele 
frequency of e.g. 4 % in Chinese11 and 1.3 % in Japanese subjects.54   
 
Polymorphism in the CYP2C19 gene is important in respect to drug metabolism as well 
as therapeutic outcome after treatment.17 The effect of CYP2C19 genetic polymorphism 
on drug metabolism is mostly studied and has the greatest clinical impact in activating 
the antiplatelet drug clopidogrel. Defective CYP2C19 alleles have been associated to 
increased risk of cardiovascular events and reduced bleeding risk in patients having 
undergone percutaneous intervention. Additionally, the RM phenotype is associated 
with increased risk of bleeding with clopidogrel treatment. Thus, dose adjustment based 
on CYP2C19 genotypes could be beneficial but is still debated.9 Furthermore, 
psychiatric patients being RMs (CYP2C19*17/*17) display lower plasma levels of 
escitalopram59,60 and imipramine,61 and the genotype furthermore predicts remission in 
patients taking citalopram, with RMs displaying lower remission rates compared with 
PMs.62 Escitalopram serum concentrations were found to be 42 % lower in patients 
homozygous for the CYP2C19*17 allele and 5.7-fold higher in PMs, compared to 
EMs.59 This correlates with previous predictions of 35-40 % lower and a 2.1-fold 
decrease in omeprazole plasma concentrations in CYP2C19*17/*17 subjects.11,63  
 
1.2.3 │ CYP2C19 gene regulation 
Besides the described genetic polymorphism, CYP2C19 enzyme activity is also affected 
by a variety of substances, including different drugs. CYP2C19 is inducible by the 
antibiotic rifampicin and the corticosteroid dexamethasone and, as will be described in 
more detail below, inhibited by estrogens. The CYP2C19 promoter region contains 
many putative transcription factor sites but the transcriptional regulation of CYP2C19 
has not been completely elucidated.64,65 It has however been shown that, like for many 
other CYPs, gene expression is up-regulated by the nuclear receptors: constitutive 
androstane receptor (CAR), pregnane X receptor (PXR), and the growth hormone 
receptor.66 Other suggested transcription factors potentially involved in the regulation of 
CYP2C19 include hepatocyte nuclear factor 3γ (HNF3γ)67 and GATA-4.68 
 
As described above, the -806 SNP in the CYP2C19 promoter region introduces a novel 
transcription factor binding site that leads to increased gene transcription of the 
CYP2C19*17 allele. This SNP was suggested to create a consensus binding site for the 
transcription family GATA.11 It was however recently discovered by our laboratory that 
the heterogeneous nuclear ribonucleoprotein L (hnRNP L) binds to this site and might 
therefore be the protein responsible for the increased gene transcription (Isa Cavaco et 
al., unpublished). 
Anna Persson 
6 
 
1.3 │ CYP2C19 activity and oral contraceptives 
Induction or inhibition of CYP2C19 mediated drug metabolism is an important aspect 
of drug assessment since it could lead to unwanted drug-drug interactions associated 
with increased risks of side-effects or therapeutic failure.1 Several studies have shown 
that exogenous estrogens affects CYP activity and most studies propose enzyme 
inhibition by these hormones.69 
 
17β-estradiol or estradiol (EE), the major endogenous estrogen in humans, and 17α-
ethinylestradiol (ETE) are the most commonly used estrogens in hormone replacement 
therapy (HRT) and oral contraceptives (OCs), respectively. OCs are among the most 
commonly prescribed drugs for women in childbearing ages with more than 60 million 
users world-wide. HRT is also commonly used for women in menopausal ages and 
therefore possible drug interactions with both OCs and HRT are important to 
investigate.70,71 Since many studies have shown drug interactions with OCs, most 
pharmaceutical companies screen for possible interactions with ETE-containing OCs 
during drug development.72  
 
Regarding CYP2C19, both in vitro and in vivo studies have shown significant inhibition 
of enzyme activity by ETE. In vitro studies in liver microsomes have shown that a high 
concentration (100µM) of ETE strongly inhibits CYP2C19 enzyme function, as shown 
by CYP2C19-specific R-omeprazole hydroxylation.70 This supports previous in vivo 
findings in healthy Swedish subjects were OCs including ETE increased the S/R-ratio 
of mephenytoin 2.5-fold and doubled the omeprazole/hydroxyomeprazole-ratio, both 
highly specific ratios for CYP2C19 activity.39 Other in vivo studies have found similar 
interactions between CYP2C19 activity and OCs.72-74  
 
Most oral contraceptives are usually combined with progestins to obtain a normal 
hormone cycle.70 The effects seen on CYP2C19 activity using combination OCs is most 
definitely due to the effect of ETE since progestins by themselves do not seem to cause 
any CYP2C19 enzyme inhibition in vivo.72,73 ETE can inhibit CYP enzymes by both 
reversible and irreversible mechanisms and it is still largely unknown and difficult to 
predict how ETE inhibit CYP2C19 enzyme function. It is however suggested that ETE 
might be a weak reversible inhibitor of CYP2C19 enzyme activity.16, 22  
1.4 │ Potential endogenous substrates for CYP2C19 
CYP2C19 has broad substrate specificity as described above and despite its important 
role in drug metabolism relatively few studies have investigated potential endogenous 
substrates. CYPs involved in the metabolism of endogenous substrates are most 
commonly involved in cholesterol, vitamin A, steroid or arachidonic acid turnover, as 
described previously. CYP2C19 is still regarded as a drug metabolizing enzyme but 
some studies suggest other functions of this enzyme in the human body that have not 
been completely elucidated yet. Most studies regarding a possible endogenous function 
of CYP2C19 have covered its role in steroid hormone metabolism. In vitro studies in 
human liver microsomes have shown that CYP2C19, together with CYP2C8 and 
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CYP2C9, effectively catalyzes the 17β-hydroxy dehydrogenation of estradiol (EE) into 
estrone (E1). EE has many different metabolites with E1 and 2-hydroxy-estradiol being 
the most important and found in higher abundance than the other metabolites. E1 was 
found to be the most abundant metabolite at lower substrate concentrations suggesting 
that CYP2C19-mediated metabolism might be the most important pathway in vivo.75 
Concentrations of EE in plasma are usually very low, ranging from around 70 pmol/L 
(postmenopausal) to 2 nmol/L, but can however be significantly higher in specific 
tissues due to local synthesis.76,77 CYP2C19 has also been shown to contribute to the 
formation of the E1 metabolite 16α-OH-estrone in liver microsomes.76  
Another suggested substrate for CYP2C19 is progesterone. In a study by Yamazaki et 
al. (1997) CYP2C19 mediated the formation of 21-OH-progesterone, and to some 
extent 16α-OH-progesterone, in human liver microsomes.78 CYP2C19 has furthermore 
been shown to oxidize testosterone to form androstenedione as a major metabolite, but 
also low levels of the metabolites: 6β-, 16β-, and 2β-OH-testosterone.78 Taken together, 
it can be hypothesized that CYP2C19 is involved in the metabolism and 
biotransformation of steroid hormones in humans. It has furthermore also been 
suggested that the CYP2C19*17 variant, leading to  increased gene expression, 
decreases breast cancer risk in women using hormone replacement therapy for more 
than 10 years. This also emphasizes the possible involvement of CYP2C19 in steroid 
hormone metabolism.79,80 
 
Apart from steroid hormones, other endogenous substrates have been proposed for 
CYP2C19. These include several different polyunsaturated fatty acids (PUFAs) e.g. 
arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid.3,81 Other members 
of the CYP2C family also contribute to this metabolism, e.g. CYP2C9 that moreover 
displays higher hepatic expression than CYP2C19. 
CYP2C19 is also suggested to be important in the metabolism of the exogenous 
cannabinoid cannabidiol and related substances thus suggesting that it could be involved 
in the metabolism of endogenous cannabinoids as well.82,83 However this remains to be 
further investigated.  
1.5 │CYP2C19, personality traits, and depressive symptoms 
For many drug metabolizing enzymes, genetic polymorphism does not render any 
obvious phenotypes without a drug challenge. This is probably due to the fact that they 
do not have a critical function in endogenous metabolism.84 From what is known today, 
CYP2C19 polymorphism does not have a clear impact on endogenous phenotypes in 
humans. Nevertheless, two studies have reported associations between CYP2C19 
polymorphism and personality traits in healthy Japanese subjects using the Japanese 
version of the Temperament and Character Inventory (TCI).85,86 The TCI investigates 
the intensity and relationship between seven personality dimensions divided into the 
temperament dimensions: harm avoidance (HA), novelty seeking, reward dependence, 
and persistence, and the character dimensions: self-directedness, cooperativeness, and 
self-transcendence.87 The first study to investigate personality dimensions and 
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CYP2C19 polymorphism found significantly lower TCI-score in HA of homozygous 
EMs compared to heterozygous EMs and PMs.86 Low scores in HA are associated with 
a carefree, courageous, outgoing, and optimistic personality and studies have previously 
found that high scores in HA is highly associated with depression and furthermore 
highly predicts MDD.88-90  
 
In the other study by Ishii et al.,85 other associations were found with female CYP2C19 
PMs scoring significantly lower on the dimensions reward dependence, 
cooperativeness, and self-transcendence, compared to EMs. People with low scores in 
reward dependence are more practical, cold, and withdrawn and low scores in 
cooperativeness are associated with a more socially intolerant, critical, unhelpful, and 
opportunistic personality.85  Low cooperativeness has also been correlated to a current 
state of depression.88 Furthermore, low scores in self-transcendence correlates with an 
impatient, unimaginative, and proud character. There was however no differences found 
between male subjects.85 
Some aspects of these studies are interesting since high scores in HA and low scores in 
cooperativeness are associated to depression, something that seems to correlate with a 
PM phenotype. However, the results from these two studies are rather inconclusive, 
with major gender differences, and should be reproduced in a larger cohort and possibly 
also other ethnic groups before any conclusion can be made regarding personality traits 
and CYP2C19 genetic variants. 
 
CYP2C19 genetic polymorphism has also been associated with depressive symptoms as 
measured by the center for epidemiologic studies depression scale (CES-D). The CES-
D scale measures depressive symptoms during the last week and consists of four 
subscales that together form the total score (T1): depressed mood, psychomotor 
retardation and somatic complaints, wellbeing, and interpersonal differences.91 Higher 
scores in all subscales indicate higher levels of depressive symptoms. In the study by 
Sim et al.,92 T1, depressed mood, and psychomotor retardation and somatic complaints 
were assessed in 1,472 subjects from the Swedish twin registry. CYP2C19*2/*2 
subjects, i.e. PMs had significantly lower T1, depressed mood, and psychomotor 
retardation and somatic complaints scores compared to EMs (CYP2C19*1/*1), 
indicative of lower depressive symptoms.92  
 
It is difficult to draw any conclusion regarding CYP2C19 genetic polymorphism and its 
effect on personality traits and depressive mood with regards to previous published 
results. Firstly, two different tests were used and TCI and CES-D scores do not measure 
the same parameters. However, previous studies have found significant association 
between high HA and high T1 scores.90 PMs score high on HA but low on T1, 
depending on the study, thus making the results contradictory. The results from the twin 
study, using CES-D scores, are however from a much larger population and can 
therefore be considered more reliable. It seems that CYP2C19 genetic polymorphism 
influence personality traits and depressive state but this remains to be further elucidated. 
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1.6 │ Major depressive disorder  
Major depressive disorder (MDD) is a common, heterogeneous affective disorder with a 
life-time prevalence of approximately 17 %,93 being twice as common in females as in 
males. MDD can be limited to a single episode but is frequently reoccurring or 
chronic.94 MDD is associated with high mortality due to the increased risk of suicide, 
and is one of the major causes of morbidity world-wide.95 The symptoms of MDD 
include persistent low mood and/or the inability to experience reward and pleasure i.e. 
anhedonia and associated symptoms. Furthermore, cognitive deficits such as poor 
concentration and impaired working memory are often a part of the symptomatology.96 
 
Although being intensively researched, the pathophysiology and neurobiology of MDD 
are still largely unknown. The etiology of MDD is partly genetic, displaying 40-50 % 
heritability as shown by large family and twin cohorts.97 However, no major risk alleles 
have been identified, supporting the hypothesis that MDD is under polygenic influence 
and that the etiology is largely influenced by environmental factors.94 MDD is mostly 
associated with polymorphism in e.g. the serotonin transporter (SLC6A4) and brain-
derived neurotrophic factor (BDNF) genes.97 These associations are logical since most 
antidepressants affect the serotonergic system97 and low BDNF levels are suggested to 
correlate with depression severity and to increase with recovery.98 Furthermore, many 
studies are investigating how environmental factors can influence the risk of MDD, both 
alone but also in combination with genetic risk. Environmental factors known to 
influence MDD are e.g. childhood adversities99 and stressful life events.100 
 
The major brain systems involved in MDD are suggested to be subcortical areas 
involved in emotion and reward processing e.g. amygdala, hippocampus, and the ventral 
striatum and cortical areas such as the (medial and lateral) prefrontal cortex and anterior 
cingulate cortical regions, highly implicated in emotion processing and cognitive 
control.94 Monoaminergic signaling is thought to be of major importance within these 
structures, both in the pathophysiology and treatment of depression. The monoamine 
deficiency theory, reduced neuroplasticity, dysregulation of the hypothalamic-pituitary-
adrenal gland (HPA) axis, and immune abnormalities are all considered important 
factors in the pathogenesis of MDD.95 
1.6.1 │ Pharmacotherapy of major depressive disorder 
Current antidepressant treatment is directed against the monoaminergic systems and is 
designed to enhance its transmission. The most commonly prescribed drugs are 
selective serotonin re-uptake inhibitors (SSRIs) such as citalopram but other treatment 
strategies also include serotonin and noradrenaline re-uptake inhibitors (SNRIs), 
monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs) and 
furthermore noradrenaline and dopamine reuptake inhibitors like bupropion, and 
noradrenergic and specific serotonergic antidepressants like mirtazapine, mainly acting 
as α2-receptor antagonists.95 Around 30 % of depressed patients do not respond to the 
treatments available,95,101,102 thus making the identification of new targets and new 
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treatment strategies extremely important for the seriously disabling and increasing 
health problem that MDD is today.  
1.7 │ Generalized anxiety disorder 
Generalized anxiety disorder (GAD) has a life-time prevalence of around 4-7 %93,103 
with females displaying an almost twice as high risk of developing the disorder.104 The 
life-time prevalence of anxiety disorders is around 30 %93 which beside GAD also 
include panic disorder, phobias, post-traumatic stress disorder (PTSD), and obsessive-
compulsive disorder (OCD). The symptomatology of GAD includes uncontrollable 
worry, anxiety, and physical symptoms like disturbed sleep, restlessness, and muscle 
tension.103 The disorder furthermore displays high co-morbidity with other psychiatric 
disorders,104 including MDD as reviewed by Kessler et al. (2008).105 It has been 
proposed by population twin studies that genetic effects are the most important common 
causes of MDD and GAD.106  
 
Compared to e.g. MDD relatively little is known regarding risk factors, genetics and 
neurobiology of generalized anxiety disorder but a heritability of approximately 15-20 
% has however been proposed.104 Neuroimaging studies suggest several brain areas 
involved in the pathophysiology of generalized anxiety disorder, most being a part of 
the so-called fear network including the amygdala, anterior cingulate cortex, and insula 
cortex. These structures seem important in both the pathogenesis and the neurobiology 
of the disorder.107,108 
1.7.1 │ Pharmacotherapy of generalized anxiety disorder 
For anxiety disorders the remission rate is poor, with between 30-50 % of patients not 
reaching full remission.109 Even without a comorbid depression antidepressants are the 
first choice in the pharmacotherapy of GAD. This includes both SSRIs and SNRIs. Also 
MAOIs are sometimes used in treatment-resistant anxiety disorders. Other treatment 
choices include the acute and often short-term use of benzodiazepines, buspiron, and the 
anticonvulsant pregabalin.110 Pregabalin resembles benzodiazepines in its mechanism of 
action, including a rapid onset of action, and does also improve depressive symptoms 
when co-morbid with GAD. Unlike benzodiazepines, no issues regarding abuse, 
tolerance and withdrawal symptoms can be seen with pregabalin. Atypical 
antipsychotics might furthermore be used in treatment-resistant anxiety disorders either 
as monotherapies or in combination with other treatments. 109 
1.8 │ The hippocampal formation and its role in psychiatric disorders 
Evidence is emerging of the involvement of the hippocampal formation in a wide range 
of psychiatric disorders including Alzheimer’s disease, schizophrenia, anxiety disorders 
and MDD.111 The hippocampus is considered a part of the limbic system with humans 
and other mammals having two hippocampi, one in each hemisphere. The hippocampal 
formation is a bilaminar grey-matter structure that consists of the dentate gyrus (DG) 
and the hippocampus proper, the cornu ammonis (CA). The CA cell layer contains 
mainly glutamatergic pyramidal neurons and based on their different properties the CA 
can be divided into the CA1, CA2, and CA3 regions, as seen in Figure 1.112 These 
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pyramidal cells together with the glutamatergic granule cells of the DG constitute 
around 90 % of the hippocampal neurons, with the remaining 10 % being mainly γ-
aminobutyric acid (GABA) producing interneurons.113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 │ The mouse hippocampus. Coronal section of the hippocampus in an adult mouse. The 
dentate gyrus (DG) contains the granule cell layer (GCL), the polymorphic layer (PL) or the hilus, and the 
molecular layer (ML). The hippocampus proper, the cornu ammonis (CA) is divided into different areas 
depending on their pyramidal neuron properties. Calbindin positive cells are seen in red and calretinin 
positive cells in green. DAPI was used as a nuclear counter stain. Photo: A Persson. 
 
The HC is one of the most connected areas in the brain, receiving its major input from 
the entorhinal cortex through the perforant pathway. The entorhinal cortex serves as the 
major connector between the hippocampus and several different cortical areas including 
the auditory and olfactory cortices, but also the amygdala.111 Despite intensive research 
on the function of the hippocampus there is still some controversy about the basic 
functions of this structure. However, its important role in the formation of episodic and 
spatial memory is widely known and generally accepted.112,114 Furthermore, pattern 
separation is thought to be essential for creating a specific memory when exposed to 
similar sensory inputs or experiences. It is believed that the DG is responsible for the 
process  of separating memories that are formed in the hippocampus.115  
 
As described above, involvement of the hippocampus in psychiatric disorders implicate 
that there are other possible functions of the hippocampus not involving memory. Even 
though traditionally considered a memory structure the hippocampal formation seems 
critically important in regulation of emotions as well.116 It furthermore seems important 
in regulating the stress response, a major risk factor for psychiatric disease.110,117  
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Functions along the dorso-ventral axis 
The hippocampus is involved in many different tasks including both cognitive and 
emotional processes. So how are all of these functions connected and regulated within 
the hippocampus? The hippocampal formation seems to exhibit significant differences 
in these functions along its dorso-ventral axis.116,118,119 Gene expression and differential 
projection patterns, mostly studied in rodents, suggest that the hippocampus can be 
divided into two separate structures; the rostral/dorsal part (posterior in primates), 
mostly involved in cognition and memory formation and the caudal/ventral part 
(anterior in primates), more implicated in emotion and stress regulation. The dorsal part 
of the hippocampus projects mostly to associational cortical areas whereas the 
caudal/ventral hippocampus on the other hand connects with the pre-frontal cortex, 
amygdala, and the hypothalamus. This theory is supported by the fact that ventral but 
not dorsal inactivation/lesions of the rodent hippocampus leads to anxiolytic behavior 
but does not seem to affect memory task performances.116,118,120 Also human studies 
indicate that that the anterior part of the hippocampus is more activated when exposed 
to an emotional stimuli or face.121 
 
Hippocampal size 
The hippocampal formation has mostly been associated to psychiatric disorders by 
observations using magnetic resonance imaging (MRI). Many studies have 
demonstrated a small reduction of hippocampal volumes, between 4-10 %, in patients 
suffering from MDD.122-125 The reduction in hippocampal volume is furthermore 
suggested to correlate with severeness and duration of the disorder.125,126 Although it 
has been questioned whether reduced hippocampal volume is merely a symptom, 
volume reductions have also been observed in for example first episode depression,127 
and in subjects with familiar high risk for MDD128 thus suggesting that reduced 
hippocampal size might also be predisposing for the disorder. Besides the effects seen 
on the hippocampal formation in MDD, reduced hippocampal volumes have also been 
associated with several anxiety disorders.129 Reduced hippocampal volumes are found 
in adult patients with chronic PTSD, when compared to healthy or trauma-exposed 
controls using MRI.130,131 Also patients with social anxiety disorder display reduced 
hippocampal volumes.132 In the same way as for MDD, reduced hippocampal volumes 
could potentially also be a risk factor for PTSD.133 The causality for the morphological 
changes seen in the hippocampus is still not known. One hypothesis suggests that the 
elevated glucocorticoid levels commonly observed in MDD patients can cause e.g. 
retraction of dendrites, decreased neurogenesis in the dentate gyrus, and loss of glial 
cells, all of which potentially could cause a smaller hippocampus.134 
 
Cognitive impairment 
Also neuropsychological studies support the involvement of the hippocampus in the 
pathophysiology of MDD, with changes in hippocampal-related tasks being connected 
to cognitive impairment in patients.134 Spatial navigation depends on hippocampal 
function and is severely impaired after hippocampal damage. In virtual reality tasks, 
patients with MDD display impaired spatial memory. These impairments have also been 
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functionally connected to abnormal activity in the hippocampus and the 
parahippocampal cortices.134 Also recollection memory is highly dependent on 
hippocampal integrity and MDD patients display impairments in recollection memory 
tasks.123  
 
Stress and the hypothalamic-pituitary-adrenal axis 
Dys-regulation of the hypothalamic-pituitary-adrenal (HPA) axis probably plays a 
central role in MDD since patients display increased cortisol levels and reduced 
negative feedback of the HPA-axis.135 The hippocampus is highly responsive to 
glucocorticoids and plays an important part in the regulation of the stress response 
through a relatively high expression of glucocorticoid receptors.110,134 Chronic stress 
and sustained levels of glucocorticoids have negative effects on learning and on the 
survival of hippocampal neurons.113,134 
 
The hippocampus is of course not by itself creating the symptoms of depression and 
other related disorders. However, the plasticity of the structure, including the stress-
sensitivity reported, this formation is most certainly playing an essential role in the 
pathobiology of several psychiatric disorders. 
1.8.2 │ Hippocampal plasticity 
Adult neurogenesis is today generally accepted to occur in two discrete regions of the 
adult brain, the subventricular zone (SVZ) of the lateral ventricles and in the DG of the 
hippocampal formation.136,137 These areas are referred to as neurogenic niches and 
neurogenesis continues throughout life for many species,138 including humans.139,140 
Neurogenesis in the DG is restricted to the subgranular zone (SGZ) and new neurons 
are integrated in the granular cell layer (GCL) as mature granule cells. The stem cells of 
the SGZ are suggested to be radial glia-like stem cells,138 also referred to as type 1 cells. 
As seen in figure X, these cells furthermore express glial fibrillary acidic protein 
(GFAP). Type 1 cells are characterized by an apical process that reaches into the 
molecular layer of the DG, suggested to be in contact with blood vessels.141 The 
maturation process of new neurons is suggested to be relatively linear with type 1 cells 
giving rise to fast-proliferating intermediate progenitor cells, type 2 cells. This cell 
population is characterized by a small soma and an irregularly shaped nucleus and is 
responsible for the large expansion of new cells seen in the DG, i.e. the expansion 
phase.  
 
Early type 2 cells, type 2a, express the stem cell marker and transcription factor Sox2. 
At this stage cell fate is determined and newborn progenitor cells either become 
apoptotic or start to differentiate into type 2b cells, expressing the immature neuronal 
marker double-cortin (DCX).141,142 The expression of DCX in these cells is linked to 
specific properties such as structural plasticity, cell migration, axonal guidance, and 
dendrite sprouting.143 DCX positive cells are frequently used as a substitute marker of 
neurogenesis, however the function of these cells during neurogenesis is still not 
known.143  DCX positive cells do however have distinctive electrophysiological 
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properties, being highly excitable, and have been suggested important roles in 
hippocampal signal processing. Furthermore they display greater synaptic plasticity 
than mature neurons and long-term potentiation is more easily induced in DCX positive 
cells compared to more mature neurons in the DG. The pool of DCX cells in the 
hippocampus is highly dependent on proliferation rates but also the degree of apoptosis 
in the maturation process.144,145  
  
 
 
 
Figure 2 │ Overview of adult hippocampal neurogenesis in the dentate gyrus. 
The neurogenesis process in the adult hippocampus is thought to be rather linear with an overall time 
frame of approximately 4-6 weeks from neural progenitor to mature granule cell. The radial glia-like stem 
cells resides in the subgranular zone (SGZ) of the granular cell layer (GCL) and give rise to fast-
proliferating progenitor cells, thus referred to as the expansion phase. The neurogenesis process seems 
critical for hippocampal function and is suggested to be involved in the pathobiology of psychiatric 
disorders. The process can be divided into different stages and by utilizing the different cell properties 
and specific markers expressed in the different phases the process can be studied in great detail revealing 
potential factors involved in its regulation. Adapted from: Schouten et al., 2012, with permission from the 
publisher.146 
 
The majority of newborn cells undergo apoptosis during the first 1-4 days of the 
differentiation process.147 During the differentiation phase cells are usually referred to 
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as type 3 cells. For the duration of this phase cells differentiate into immature neurons 
and migrate into the granule cell layer. At the end of the differentiation process cells 
develop and elongate their dendritic trees toward the molecular layer of the DG and 
their axons towards the CA3 area.114,141 The whole process from stem cells to mature 
granule cells takes approximately 4-6 weeks during normal conditions.142 The 
neurogenesis process is usually divided into different phases, with several specific cell 
markers for each phase, as visualized in Figure 2. This gives the opportunity for a more 
in detail study of the different cells involved and factors that affect hippocampal 
neurogenesis.141 Numerous studies have investigated the effects of e.g. antidepressants, 
stress, and exercise on neurogenesis in the DG and the neurogenesis process is shown to 
be extremely dynamic in rodents.114,142,148  
 
BrdU and Ki-67 
The lack of knowledge regarding neuronal stem cells has made it difficult to detect and 
study this specific cell population. However, the discovery of the exogenous thymidine 
analog 5-bromo-2’-deoxyuridine (BrdU) made it easier to study proliferating cells and 
their survival rates in the neurogenic niches of the brain. BrdU is injected in the rodents 
and is incorporated in the DNA during the S-phase of the cell cycle.149 BrdU is however 
toxic and Ki-67, another proliferation marker, has gained increased popularity for 
studying proliferation rates. Ki-67 is endogenously expressed during the whole mitotic 
period and requires less preparation compared to BrdU, both with regards to 
pretreatment of the animals but also the tissue, since the immuno-labeling requires 
denatured DNA for proper visualization of BrdU.150 However, one of the major 
advantages of BrdU compared to Ki-67 is that after BrdU incorporation it can be 
visualized for a long time thus enabling studies of cell survival and cell fate in the 
neurogenesis process.149 BrdU and Ki-67 labeled cells usually display rather similar 
numbers when examined acutely after BrdU injection.150  
 
Adult neurogenesis and disease 
Adult neurogenesis is important for hippocampal function with a critical role in 
hippocampal-dependent learning and memory formation.114,151 The large pool of DCX 
positive cells in the DG is thought to be available for encoding new experiences and 
DCX cell numbers have been shown to adapt in rodents depending on how often the 
hippocampus is challenged with novel stimuli.152,153 Furthermore, recent studies suggest 
that hippocampal neurogenesis is not only regulated by stress but can in fact also buffer 
or regulate the stress response.110,117 Another important and interesting aspect is if 
hippocampal neurogenesis can affect other hippocampal-related behaviors such as 
depressive mood. The neurogenesis hypothesis postulated for both affective and anxiety 
disorders is based on the hypothesis that reduced neurogenesis in the DG is causative 
for the psychopathology seen and that treatments available are dependent on restored 
neurogenesis levels for a successful response.142 It has furthermore been suggested that 
the volumetric changes in HC volume seen in MDD and anxiety disorders are due to 
reduced neurogenesis in the DG. These hypotheses have been the topic for many 
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studies, mostly in rodents, but there are still no conclusive data supporting these theories 
and the subject is still under intense discussion and investigation.142 
1.9│ Modeling human psychiatric disorders in mice 
For investigating gene function and for modeling human psychiatric disorders 
transgenic expression and genetic manipulation of target genes in animals is an 
important and valuable tool.154,155 These techniques are mostly developed in mice and 
due to these advantages the mouse is still the most commonly used species for 
transgenic expression and gene manipulation.154 However, new transgenic rat models 
are developed and this would provide a better model in neuroscience and behavioral 
pharmacology where the rat in many aspects is the preferred animal model.156  
 
The usefulness and validity of animals as human disease models must be evaluated 
carefully and three aspects are generally considered. Construct validity referrers to the 
etiology of the disease, i.e. the effect of a human gene causes similar conditions in the 
animal model. Face validity incorporates the symptoms of the disease into the validation 
of the model, i.e. the behavioral symptoms display common features. Many psychiatric 
disorders are rather complex and therefore also endophenotypes including 
neuroanatomical pathology and neurophysiological responses can be regarded as face 
validity. Predictive validity on the other hand takes in to account the treatment aspect of 
the modeled disease. Classes of drugs that reverse the human symptoms must similarly 
be effective in the model.157 
 
It is rather obvious that mice are not ideal models of human psychiatric disorders, 
mainly due to the great differences in brain anatomy, and we can never truly know 
whether a mouse is anxious or feeling depressed. However, the validity aspects 
described above are based on similarities in etiology, symptomatology, and treatment 
aspects and makes it possible to objectively investigate genetic variants or new 
treatments strategies for anxiety and depression in mouse but also rat models. 
1.9.1 │ Rodent models of mood disorders 
The pathophysiology of mood disorders is still largely unknown and this is partly due to 
the lack of valid animal models. The main reason for the difficulties in finding good 
models for elucidating the pathophysiology is probably due to the fact that e.g. MDD 
and other mood disorders are so heterogeneous. Furthermore, many of the core 
symptoms of human depression are not possible to study in animals. These include e.g. 
depressed mood and suicidality. Due to these major issues most animal models of 
depression today are based on two major principles: predicting antidepressant effects or 
response to stressors.158 
  
Two of the most commonly used behavioral tests for assessing antidepressants are the 
forced-swim test (FST or Porsolt’s test) and the tail-suspension test (TST).159,160 Both 
tests present inescapable environments that initially engage in intensive escape-oriented 
movements that eventually proceed into immobility or despair behavior. 
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Antidepressants give an acute increase in escape-oriented behavior and these tests are 
widely used as rapid screening tests for novel antidepressants due to their predictive 
validity. This does however raise some concerns regarding which systems that are 
involved since the FST and TST are sensitive to acute administration of antidepressants 
whereas a more chronic treatment is required for clinical efficacy in humans. These 
tests are also frequently used as phenotypic screens of rodent models to assess 
depressive-like behaviors. Increased basal immobility can in this respect be interpreted 
as increased depressive-like behavior and decreased immobility as a sign of an 
antidepressive phenotype.161 However, since the basis of the behavior in these tests is 
rather unknown it is also likely that the response seen, without pharmacological 
manipulation, might have more to do with stress coping than anything else.162  
The learned-helplessness model is another test that can be used to study active versus 
passive stress coping strategies in rodents. Rodents frequently exposed to inescapable 
foot shocks are subsequently incapable of fleeing even when offered a possibility. Not 
all rodents develop helplessness and it is by no means a chronic state since it usually 
only persists for 2-3 days, but antidepressants do however reverse this despair behavior 
giving predictive validity to this behavioral model.158 
 
Inability to cope with stressors is one of the major known risk factors of mood disorders 
as described above and the previously described models have stress coping as an 
important aspect of the behavioral response. However, the most commonly used stress-
related rodent models are chronic mild stress and early life stress paradigms such as 
maternal separation.161 Chronic mild stress paradigms include a variety of mild 
unpredictable stressors, are more validated than early life stress models, and do in many 
cases display construct, predictive, and face validity of specific depression 
endophenotypes.163 Anhedonia is defined as a reduced interest in normally pleasurable 
things. It is a core symptom of human depression and an endophenotype that can be 
modeled in rodents and is usually an acquired phenotype after chronic mild stress. 
Anhedonia in rodent models is usually assessed by investigating the preference for a 
highly palatable solution, e.g. sucrose over water.161 
 
There are a few validated genetic rodent models of human depression with one example 
being the Flinders sensitive line (FSL) rat. This strain was initially developed through 
selective breeding for increased cholinergic sensitivity but was shown to display several 
important features of human depression.164 One interesting and important aspect is that 
the FSL rat displays antidepressant effects after chronic treatment with a wide variety of 
antidepressants, thus displaying high construct validity.165   
1.9.2 │ Rodent models of anxiety disorders 
Anxiety is usually defined as a pathological response to fear, with the fear response 
being stronger than the situation requires and usually persisting for longer periods of 
time. Animal models of anxiety were initially based on the anxiolytic effects of 
benzodiazepines. The models are therefore not always so suitable for assessing new 
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anxiolytic agents. Animal models of anxiety can be classified into conditioned and 
unconditioned tests. Both groups of assessments measure the response to stressful 
stimuli but conditioned models often include painful events e.g. electric foot shocks. In 
this thesis only unconditioned models will be addressed since the other models usually 
involves memory and nociception influences and unconditioned responses are 
furthermore the most commonly used anxiety models for mice.166,167 However, none of 
the tests described here are thought to display pathological anxiety-related behaviors but 
are most commonly referred to as models of state anxiety. State anxiety refers to the 
response to the level, or type of stress, at a specific moment whereas trait anxiety does 
not vary from moment to moment but is a persistent feature of animal behavior. Trait 
anxiety models are most commonly specific strains displaying high anxiety behavior or 
knock-out mice,167,168 with one example being the 5-hydroxytryptamine1A receptor 
knock-out mouse model.169,170 
 
Most unconditioned tests are based on the fact that small rodents have an innate 
aversion for open and brightly lit spaces and the conflicting nature of being exploratory 
animals.161,166 These test include e.g. the open-field, elevated plus maze, elevated zero 
maze, light-dark box etc. Avoidance of the aversive environment in these tests displays 
some face validity since avoidance of fearful situations or objects is a common feature 
of human anxiety disorders. However, it is important to remember like for most 
depression models, anxiety tests mostly display predictive validity, i.e. the aversive 
behaviors seen in the tests are reduced by anxiolytic treatment.166 However, since the 
aversive behavior also can be augmented with drugs that induces anxiety in humans 
these tests are also utilized for evaluating anxiety-like behavior in mutant mice.161 Also 
stress-induced hyperthermia displays predictive validity for anxiolytic drugs, with 
treatment reducing the increase in body temperature normally observed after exposure 
to a stressor.171 
1.9.3 │ CYP2C18/CYP2C19 transgenic mice 
Mice transgenic for the whole human CYP2C18 and CYP2C19 gene locus were 
produced at the Astra Zeneca Transgenic Centre in Mölndal, Sweden. The mouse model 
was created by pronuclear injection in C57Bl/6 eggs with a bacterial artificial 
chromosome (BAC RP11-466J14), containing the whole human CYP2C18 and 
CYP2C19 gene locus. The 5’ end of the inserted gene fragment is located at position -
5828 base pairs (bp) from the start codon of the CYP2C18 gene and the 3’ of the insert 
at +30,869 bp from the end of exon nine of the CYP2C19 gene, thus also containing 
potential cis-regulatory regions. This created a total gene fragment of 196 kb, 
incorporated into the mouse genome. The number of copies incorporated was estimated 
to approximately 12 using real-time polymerase chain reaction (RT-PCR) and human 
genomic DNA as a reference. The incorporated gene fragments were furthermore 
analyzed using fluorescent in situ hybridization (FISH) to determine chromosomal 
location. A single insertion site was found at region C1 on mouse chromosome 2. For 
further details see Löfgren et al. (2008).172  
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In previous publications CYP2C18/19 transgenic mice are named tg-CYP2C18 & 19. 
However, in the most recent paper,173 included in this thesis, these mice are referred to 
as CYP2C19Tg mice due to the  improbability of any CYP2C18 contribution to the 
observed phenotype. CYP2C18 displayed high mRNA levels in both male and female 
transgenic mice (26-31 weeks of age), comparable to CYP2C19 levels, with high 
expression in liver, kidney and small intestine. However, no CYP2C18 protein was 
detected in any of the tissues investigated. This confirms previous studies since the 
human CYP2C18 protein has never been detected in human tissues despite high mRNA 
levels.36,174 
 
Even though hemizygous CYP2C19Tg (CYP2C19Tg-Hem) mice exhibit around 12 
copies of the human genes Western blot (WB) analysis only found an approximately 40 
% increase in CYP2C/Cyp2c (human/mouse) protein levels, something that was also 
confirmed by activity assays in liver microsomes. This is most probably due to 
background levels from the relatively large mouse Cyp2c family (see 1.9.3). 
CYP2C19Tg-Hem mice do not display any macroscopic or histologic pathology but do 
however exhibit some differences in organ weight and clinical pathology with e.g. 
lower brain weights in both male (4.3 % lower) and female mice (5.9 % lower). The 
CYP2C19Tg-Hem mice are nevertheless considered viable and healthy.175 
 
As an attempt to confirm data produced within this thesis two other transgenic founders 
were also evaluated. The BAC used in the generation of the mice described above was 
modified by deleting exon 7-9 in the CYP2C18 gene. This was done in collaboration 
with Polygene Inc. to further ensure that the phenotype seen was due to CYP2C19 and 
not CYP2C18 enzymatic activity. The two transgenic founders were produced by Duke 
University but did unfortunately display low copy number of the genetic insert (3 and 5 
copies, respectively) and brain expression could not be detected, indicating that the 
deleted region could be important for expressional regulation of the CYP2C19 gene. 
1.9.4 │ Mouse Cyp2c family 
Compared to the human CYP2C-family with only four genes (CYP2C8, CYP2C9, 
CYP2C18, and CYP2C19) the mouse family has expanded to one of the most complex 
CYP families with 15 functional genes located on chromosome 19.176,177 It is difficult to 
compare CYP2C genes between humans and mice due to the difference in number and 
sequence variation. However, the human CYP2C19 gene is relatively homologous to 
three genes in the mouse 2c-cluster namely Cyp2c37, Cyp2c50, and Cyp2c54 (DNA 
identity: 77.9-78.5 %).178 The mouse Cyp2c family is not so well characterized but do 
however display great variety in tissue distribution and metabolic activity, being mainly 
involved in endogenous functions like e.g. AA and linoleic acid metabolism.179,180 
 
Recently a mouse Cyp2c knock-out (KO) was created and characterized with 14 out of 
the 15 Cyp2c genes deleted from the mouse genome. This model can be used as a basis 
for more humanized mouse models to investigate effects of a single human CYP2C 
gene insert without the possible background effects of the numerous endogenous 
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enzymes. The Cyp2c KO has been a basis for a CYP2C9 humanized mouse model 
intended for investigations of  CYP2C9 drug metabolism and drug-drug interactions.177
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2 │ Aims 
The general aim of this thesis was to study CYP2C19 with regards to a possible 
endogenous function of this enzyme. The aim was furthermore to investigate the effects 
of estrogens on CYP2C19 gene regulation and metabolic activity.  
The specific aims were:  
I.   Develop a cell system stably expressing CYP2C19 that can be used as a 
screening tool for potential substrates and inhibitors.  
II.    Investigate if estradiol and 17α-ethinylestradiol have any direct effects on 
CYP2C19 enzyme activity in vitro. Furthermore elucidate if and how 
CYP2C19 gene expression is regulated by these estrogens. 
III. Investigate endogenous functions of CYP2C19 by characterizing a 
CYP2C19 transgenic mouse model with regard to brain development and 
morphology and behavior. 
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3 │Methodological considerations 
The work included in this thesis spans over many aspects of CYP2C19 gene regulation 
and function, from in vitro cell experiments to in vivo studies in transgenic mice. In this 
section methodological considerations are raised for further understanding regarding 
methods used and validation of animal experiments. 
3.1 │ Paper I – Regulation of CYP2C19 expression by estrogen receptor α: 
implications for estrogen-dependent inhibition of drug metabolism 
The main aim of stably transfecting HEK293 cells with CYP2C19 cDNA was to 
develop an in vitro system that could be used as a screening tool for potential 
endogenous CYP2C19 substrates. Several candidates from more high-throughput 
screenings have been tested in this cell system with results not yet published. In the first 
paper the HEK293 cell line stably expressing CYP2C19 was produced and used to 
study the direct effects of 17α-ethinylestradiol (ETE) and estradiol (EE) on CYP2C19 
enzyme activity. Estrogens were also investigated with regards to their effect on 
CYP2C19 gene regulation, something that is described in further detail in paper I. 
3.1.1 │ CYP2C19 stable cell line 
Establishing a cell line expressing CYP2C19 was achieved by using the Flp-In™ 
system from Invitrogen and their modified HEK293 cell line, Flp-In™-293, containing 
a single integrated Flp recombination target (FRT) site ensuring a single integration site 
of the CYP2C19 gene. 
CYP2C19 cDNA was subcloned into the pcDNA5/FRT expression vector and 
homologous recombination between the FRT sites in the cells and vectors was 
performed using the Flp recombinase, pOG44. Mock transfected cells were prepared in 
the same way with the pcDNA5/FRT vector and were used as controls in all 
experiments. After transfections cells acquired Hygromycin B resistance and resistant 
clones were sub-cultured and further analyzed. CYP2C19 expression and enzymatic 
function in the stable cell line was validated by RNA and protein expression by 
performing real-time polymerase chain reaction (RT-PCR), immunocytochemistry 
(ICC) and western blotting (WB), and by studying enzyme activity in intact cells.  
3.1.2 │ Enzyme activity assay  
When studying CYP enzyme activity many different systems and assays can be used. 
The P450 Glo assay from Promega contains the CYP2C19 specific substrate Luciferin-
H EGE and was used for measuring the effects of 17α-ethinylestradiol (ETE) and 
estradiol (EE) on CYP2C19 enzyme activity. Flp-In™-293/CYP2C19 cells were seeded 
in 96-well plates and incubated with the CYP2C19 substrate. Estrogens were added 5 
minutes prior to substrate incubations and the luminescence produced was proportional 
to CYP2C19 activity. 
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3.2 │ Paper II - Decreased hippocampal volume and increased anxiety 
in a transgenic mouse model expressing the human CYP2C19 gene 
3.2.1 │ Transgenic mice 
All mice included in this study were of C57BL/6 background and transgenic for the 
human CYP2C18 and CYP2C19 genes or wildtype (Wt) controls. The mouse model 
investigated, transgenic for the whole human CYP2C18 and CYP2C19 locus were 
originally developed and produced at Astra Zeneca Transgenic Centre in Mölndal, 
Sweden. CYP2C19 transgenic mice hemizygous (CYP2C19Tg-Hem) for the gene insert 
express approximately 12 copies and have previously been characterized with regards to 
gene regulation, expression and pathology.172,175,181 For a more detailed description see 
1.9.3. 
  
CYP2C19 appears to have drastic effects on development at high expression levels 
since pups homozygous (CYP2C19Tg-Hom) for the insert rarely survive past postnatal 
day 3 (PND3). CYP2C19Tg-Hom mice were therefore only bred for in the 
developmental part and for PND0 brain morphology assessments.  For all experiments 
male CYP2C19Tg-Hem mice were investigated and generated by crossing 
CYP2C19Tg-Hem and wild-type (Wt) mice. For all experiments, except for the tail-
suspension test without stress, CYP2C19Tg-Hem females were used to avoid any 
potential maternal environmental differences between the litters. For the same reason 
Wt litter mates were always used as controls. Early in the characterization of the 
CYP2C19Tg-Hem mice a specific motoric phenotype was observed, where one or both 
hind paws were lifted higher, and sometimes stayed elevated for longer than in Wt mice. 
This phenotype does not seem to affect the animals overall performance in the 
behavioral tests as will be described in further details in the results and discussion part. 
Male mice were used for all experiments apart from the developmental study were 
genders were unknown. This choice was made to avoid additional variables such as 
hormonal fluctuations. It has already been shown that CYP2C19 display a sexually 
dimorphic expression pattern in the transgenic mice so differences in the phenotype 
could be expected between genders. All mice were group-housed with a 12h light/dark 
cycle and with ad libitum access to food and water. Every effort was made to minimize 
animal suffering and number of individuals that had to be sacrificed during the work of 
this thesis. All animal experiments were approved by the Stockholm Northern Ethics 
Board of Animal Experimentation.    
3.2.2 │ Behavioral studies 
When starting this thesis work little was known about the phenotype of the 
CYP2C19Tg-Hem mice in regards of behavior and brain morphology and function. As 
described above an association has however been discovered between CYP2C19 
genotype, more specifically low enzyme function, and less depressive symptoms.92 We 
therefore decided to start with a behavioral investigation of male CYP2C19Tg-Hem 
mice at 7 and 15 weeks of age as a first step in elucidating a possible endogenous 
function for CYP2C19. A battery of behavioral tests was evaluated in the transgenic 
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mice trying to cover important aspects such as motor function and activity, depressive- 
and anxiety-like behavior, and stress sensitivity. 
  
To avoid any unnecessary stress for the animals all mice were handled by the 
experimenter the week before behavioral testing for at least one minute per day for four 
consecutive days. On test days, all mice were acclimatized to the test room for one hour 
before proceeding with behavioral tests. All assessments were performed at both ages 
apart from the Morris water maze (MWM) that was only investigated in 15-week old 
mice. The tail-suspension test (TST) was performed with and without prior exposure to 
the MWM on separate groups of mice. All other behavioral tests were performed on the 
same group of mice at both ages. Mice were left to rest for at least three days between 
tests that were conducted in the following order: Open-field (OF), light-dark box 
(LDB), and stress-induced hyperthermia (SIH). 
 
3.2.2.1 │ Tail-suspension test (TST) 
For investigating and validating antidepressant drugs, the TST is one of the most 
commonly used tests in drug development today. It is based on the behavioral despair 
monitored in mice exposed to the short-term stressor of being suspended by the tail 
above the ground.160 The forced swim test is also widely used in the same way as the 
TST but these tests are generally displaying similar outcomes and therefore only the 
TST was used for the initial screening in this study.160 The main goal of this study was 
not to investigate antidepressant drugs but to study any potential phenotype of the 
CYP2C19Tg-Hem mice when exposed to this test.  
All mice were exposed to the TST for 6 minutes and immobility time (>2s), frequency 
and latency to first immobility were manually calculated for the whole session. The TST 
was performed on 7-week old and 15-week old male mice (n=6-10/group). Three days 
after being exposed to the MWM, separate groups of mice were subjected to the TST to 
investigate if the stress of water maze exposure could potentially change the outcome of 
this test (Wt: n=10; CYP2C19Tg-Hem: n=9). The test was performed and evaluated in 
the same way as described above. 
3.2.2.2 │ Open-field (OF) 
The open-field paradigm was used for the evaluation of locomotor activity since the 
CYP2C19Tg-Hem mice display a walking phenotype, as described in 3.2.1. All mice 
were placed in the same position in square opaque Plexiglas boxes (50 cm3) without 
bedding (n=15/group). The OF is furthermore considered an unconditioned conflict test 
for assessing anxiety-like behavior with the open illuminated arena being potentially 
threatening for small rodents.166,167 To analyze anxiety-like behavior in the OF, the 
arena was divided into peripheral, intermediary and central regions. Total distance 
travelled and time spent in each area was calculated using recordings and the behavior 
analysis software TopScan Lite from Clever Sys Inc. 
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3.2.2.3 │ Light-dark box (LDB) 
The LDB evaluates mouse aversion to illuminated open areas and the desire of 
exploring new environments182 and is one of the most commonly used behavioral tests 
for assessing anxiety-like behavior in mice.183 The light-dark box consisted of two 
compartments: one dark, closed compartment (25 cm3) and one illuminated, open 
compartment (25 cm3). All mice were placed in the light compartment facing away from 
the opening and were allowed to freely explore for 5 minutes (n=15/group). Time spent 
in and number of transitions between the different compartments was recorded. 
 
3.2.2.3 │ Stress-induced hyperthermia (SIH) 
The SIH, mostly used for its predictive validity by using anxiolytic drugs, was 
employed to further investigate the stress response in the transgenic mice.171 Rectal 
temperature was measured twice in each mouse: t=0 (T1) and t=+10 min (T2). After the 
first measurement (T1), each mouse was placed individually in a novel cage for 10 
minutes (n=15/group). The T1 handling plus the 10-minute exposure to a novel cage 
was considered stressors, the response to which was analyzed by temperature raise at 
T2. The difference in temperature (∆T= T2 -T1) is considered to reflect stress-induced 
hyperthermia.171 This test was not included in paper II due to space limitations. 
 
3.2.2.4 │ Morris water maze (MWM) 
Spatial navigation learning in the MWM is highly correlated to hippocampal function in 
mice. This is best described by studying the effects that MWM training has on 
neurogenesis and survival of GCs in the hippocampus. Several studies have shown that 
learning in the MWM selectively adds and remove adult-born GCs depending on their 
maturation stages and functional significance, thus suggesting that these cells and 
hippocampal plasticity is highly involved in the learning process.184,185 Due to the 
drastic changes in hippocampal size and neuron maturation in the transgenic mice the 
MWM was employed to evaluate if these changes have any effects on spatial learning, 
i.e. hippocampal function. This was assessed in 15-week old male mice in a water pool 
measuring 120 cm in diameter. A transparent platform (10 cm) was placed in the north-
west quadrant with four visual cues placed around the pool. For a more detailed 
description see Figure 9a. All mice were assessed for motivation and swim capacity in a 
pre-training session, revealing no obvious problems. Three days after the pre-training 
assessment all mice were trained in the water maze four times a day for five consecutive 
days. During the training sessions the platform was hidden and all mice were placed in 4 
different random positions per day: north, west, south, and east. To be considered a 
successful response during the training sessions the mice had to stay on the platform for 
three seconds. During the retention test, 1 day after the last training session, the mice 
were placed in the south-east corner of the pool and left in the water for 60 seconds. 
During the retention test the platform was removed and learning and memory evaluation 
was accomplished by manually calculating time to first platform crossing, number of 
platform crossings and total time spent in the platform quadrant.   
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3.2.3 │ Acute restraint stress and plasma corticosterone levels 
To investigate stress reactivity of the mice, including hippocampal neuronal activation 
and the function of the hypothalamic-pituitary-adrenal (HPA) axis, both 7- and 15-
week-old mice were exposed to acute restraint stress. This was achieved by placing the 
mice in a 50 ml ventilated Falcon tube for 30 minutes. To collect whole blood mice 
were either directly decapitated after the restraint stress or placed in their home cage for 
another 30 minutes before decapitation. As a control, mice were immediately 
decapitated without stress exposure. All animals in the same age group were decapitated 
on the same day, between 08:00 and 11:00 a.m. Serum aliquots were analyzed for 
corticosterone (CORT) content using an enzyme-linked immunosorbent assay specific 
for mouse/rat corticosterone. To investigate hippocampal activation after stress 
exposure all hippocampi were dissected and analyzed the expression of the immediate-
early gene c-fos. 
3.2.4 │ mRNA expression and RT-PCR 
CYP2C19 and CYP2C18 expression levels were investigated in liver and brain tissue 
during mouse development, embryonic day 11 (E11), E14, and E18, early post-natal 
days, post-natal day 0 (PND0), and PND7, and at 7 weeks of age. In four additional E18 
transgenic embryos, the hippocampus and cortex were dissected out to investigate 
specific expression within the different areas. The hippocampi had to be pooled due to 
their low weight. RT- PCR protocol and primers were obtained from Löfgren et al. 
(2008).172  
3.2.4.1 │ Human fetal samples 
To validate the developmental findings in the CYP2C19 transgenic mice brain tissue 
from three human fetuses was obtained from the NICHD Brain and Tissue Bank for 
Developmental Disorders at the University of Maryland (Baltimore, MD). A total of 8 
samples were therefore analyzed for CYP2C19 mRNA expression. Samples were from 
3 different female Caucasian donors; gestational week 19, 24 and 39. Brain samples 
were from different cortical areas with little or no overlap between donors. All samples 
were processed and analyzed in the same way as described for human CYP2C19 
expression in the transgenic mice but with the human housekeeping gene: 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
3.2.5 │ Brain morphology studies 
 
3.2.5.1 │ Newborn CYP2C19Tg-Hom mice 
CYP2C19Tg-Hom mice displayed high neonatal lethality and in an attempt to 
investigate any possible reasons for this extreme phenotype, brain morphology was 
evaluated at postnatal day 0 (PND0) in CYP2C19Tg-Hom (n=4), CYP2C19Tg-Hem 
(n=5) and Wt (n=3) pups. To elucidate any differences in brain morphology cresyl 
violet stained sections were blinded and visually assessed. After this initial assessment 
sections from three CYP2C19Tg-Hom and three Wt mice were further analyzed and the 
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cortex, hippocampus and central regions were manually outlined in all sections to get an 
estimated over some main morphological findings. 
 
3.2.5.2 │ 7- and 15-week old CYP2C19Tg-Hem mice 
One of the most severely affected structures in PND0 CYP2C19Tg-Hom mice was the 
hippocampus and therefore hippocampal size was assessed in 7- and 15-week old 
CYP2C19Tg-Hem mice and Wt controls. To cover the whole hippocampal formation 
every 7th coronal section, with a total number of 12 sections starting at Bregma -0.94 
mm, was stained with cresyl violet and the hippocampi were manually outlined in all 
sections, see Figure 3.  
 
3.2.5.3 │ Magnetic resonance imaging 
In collaboration with Karolinska Experimental research and imaging center (KERIC) a 
magnetic resonance imaging (MRI) study of 15-week-old CYP2C19Tg-Hem mice 
brains and Wt controls was performed. This was done to confirm previous size 
measurements in brain sections and was performed by using a horizontal 9.4 T Varian 
magnet. The volumetric images were acquired using a 3D Inversion Recovery Fast 
Spin-Echo Sequence and image analysis was made with the image analysis software 
ITK-SNAP (www.itksnap.org).186 Hippocampi and whole brain volumes (including 
cerebellum) were manually outlined with genotypes blind to the experimenter. 
 
 
Figure 3 │ Image of a whole mouse brain and one coronal section visualizing the hippocampal 
formation. (a) Mouse brain with approximate lines representing the 40 µm coronal sections made for 
immunohistochemical assessments. The most rostral section was located approximately at Bregma -1.46 
mm and every 7th section, with a total of 8 sections was processed for different markers. Similar 
sectioning was done for area measurements of the hippocampal formation but with a total of 12 sections 
starting at Bregma -0.94 mm. Arrows indicate section seen in (b). (b) Coronal section of mouse brain 
stained with cresyl violet. As clearly visualized in the section the hippocampal formation is present in 
both hemispheres. The black box indicates one hippocampus. Brain in (a) adapted from: 
http://www.nervenet.org. Photo: A. Persson. 
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3.2.6 │ Immunohistochemistry 
For all brain immunohistochemical (IHC) stainings mice were perfused with 4 % 
paraformaldehyde to acquire a quick preservation of the tissues and antigens and to 
avoid any hemoglobin auto-fluorescence. Brains were coronally sectioned into 40 µm 
thick sections as seen in Figure 3, to perform all stainings in free-floating. For all IHC 
markers, total numbers were also corrected for total hippocampal volumes as measured 
by MRI. 
Cell proliferation and maturation of young neurons is important for hippocampal 
function. It is furthermore suggested that the reduced hippocampal size can be caused 
by reduced neurogenesis in the DG of the hippocampus.142 Therefore 7-week-old mice 
were injected with bromodeoxyuridine (BrdU) to investigate cell proliferation and 
survival. Ki-67, another proliferation marker was used as a control for 7-week-old mice 
and for assessing proliferation rates in the DG in adult mice. In 15-week old mice the 
number of immature, migrating neurons in the DG was assessed by staining for DCX 
positive cells. 
Additionally, number of parvalbumin (PA) positive cells was evaluated in the whole 
hippocampal formation at 15 weeks of age. Number of cells for all markers was 
manually assessed in the DG of the hippocampal formation. PA positive cells were also 
assessed in the CA1+2 and the CA3 regions of the mouse hippocampus.
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4 │ Results and discussion 
In the following section results from the two papers included in this thesis will be 
discussed. For a more detailed description of the result, including statistics, see 
respective paper. 
4.1 │ Paper I – Regulation of CYP2C19 expression by estrogen receptor α: 
implications for estrogen-dependent inhibition of drug metabolism 
The CYP2C19 enzyme is involved in the metabolism of many drugs on the market and 
it is therefore important to identify all factors that affect enzyme expression. 
Polymorphism in the CYP2C19 gene is well characterized and makes it possible to 
divide the population into different metabolic phenotypes. However, other factors 
besides genetic polymorphism also influence CYP activity, including drugs and other 
substances that are known to either induce or inhibit CYP2C19 gene transcription and 
enzyme activity. As described in the introduction, estrogens are shown to be 
metabolized by CYP2C19 and furthermore to inhibit enzyme activity, however by 
which mechanisms this is achieved and its clinical implications warrants a more in 
detail investigation. Both transcriptional regulation and direct enzyme inhibition of 
CYP2C19 could be envisioned and was further investigated in this paper.  
4.1.1 │ Validation of the CYP2C19 stable cell line 
To investigate direct effects of the estrogens ETE and EE on CYP2C19 enzyme activity 
a HEK293 cell line stably expressing CYP2C19 was established by using the Flp-In™ 
system (Invitrogen). RT-PCR and WB confirmed CYP2C19 mRNA and protein 
expression in the HEK293 cells. CYP2C19 protein expression was also confirmed by 
ICC as visualized in Figure 4. The HEK293 cells originate from transformation of 
human embryonic kidney (HEK) cells by exposure to sheared fragments of human 
adenovirus type 5.187 HEK293 cells are widely used for both transient and stable 
expression of recombinant proteins due to their efficiency and consistency  in 
transfections and protein expression.188,189 This cell line has been further modified by 
Invitrogen, referred to as Flp-In™-293 cells, to ensure a single integration site of your 
gene of interest, thus making the Flp-In system ideal for fast, predictable and stable 
protein expression. I have furthermore used the HEK293 cell line, stably expressing the 
CYP2C19 enzyme, for inhibitor screening and to investigate possible endogenous 
substrates for CYP2C19, something that will be addressed in future publications. 
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Figure 4 │ CYP2C19 protein expression in the modified HEK293 cell line, Flp-In™-293 
(Invitrogen). Flp-In™-293 cells were stably transfected with CYP2C19 cDNA and protein expression 
was confirmed by immunocytochemistry using the anti-CYP2C19 antibody produced in rabbit (Sigma-
Aldrich). (a) Mock transfected cells were used as controls in all experiments. (b) CYP2C19 transfected 
Flp-In™-293 cells. Scale bar= 50 µm. The inserted images are magnifications (63x) of one representative 
cell. Scale bar= 5 µm. Photo: A. Persson 
4.1.2 │ Relatively high estrogen concentrations inhibit CYP2C19 enzyme 
activity 
The estrogens 17β-estradiol (EE) and 17α-ethinylestradiol (ETE) are the most 
commonly used female steroid hormones in hormone replacement therapy and OCs.70 
Drug interactions caused by these hormones are important to investigate in the 
development of new drugs since these estrogens are widely prescribed and studies show 
that female hormones can affect the activity of drug metabolizing enzymes, with some 
enzymes being induced and others displaying substantial inhibition.69,70,72 As described 
in the Introduction (section 1.3), in vivo data shows that the interaction of OCs and 
CYP2C19 specific substrates seems to be substantial, displaying a marked reduction of 
CYP2C19 specific metabolites.39,50,72-74 In this paper we showed that both EE and ETE 
have a direct inhibitory effect on CYP2C19 enzyme function, thus confirming 
previously published data. However, all in vitro data published hitherto, including this 
study, have used rather high ETE concentrations in the micromolar range.70 Plasma 
levels of ETE after using OCs is usually in the pico- to nanomolar range making the 
published results rather questionable from a clinical perspective.71 Female sex steroids 
do however display an extensive enterohepatic circulation which could lead to relatively 
high hepatic concentrations, despite low plasma levels.70 Thus, it is still rather 
questionable if the high estrogen concentrations needed for significant enzyme 
inhibition in the CYP2C19 expressing cells can explain or even contribute to the 
marked effects OCs display on CYP2C19 metabolism in human studies.39,50,72-74 It was 
thus considered important to evaluate effects on the transcriptional level. 
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4.1.3 │ Estrogens affect CYP2C19 enzyme activity through transcriptional 
regulation 
The main focus of this study was therefore to investigate if ETE and EE could affect 
transcriptional regulation of the CYP2C19 gene. In this paper, four potential estrogen 
responsive element (ERE) half-sites were discovered in the promoter region of the 
CYP2C19 gene by in silico analysis. However, only one site, in the promoter region; 
position -151/-147, showed binding of estrogen receptor α (ERα) by electrophoretic 
mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) analysis in 
human hepatoma (Huh7) cells. It was confirmed that ERα is activated by ETE and EE 
and inhibits CYP2C19 transcription through the newly identified ERE binding half site 
(-151/-147) in the proximal part of the CYP2C19 5’-flanking region. EE and ETE 
displayed inhibition of CYP2C19 gene transcription in a dose-dependent manner with 
the half-maximal inhibitory effect of 100 and 10 nM, respectively. This was displayed 
both by luciferase gene reporter assay and by measuring mRNA levels in human 
hepatocytes. A similar transcriptional regulation has also been suggested for the related 
CYP2C9 gene indicating that this regulatory mechanism is rather conserved in the 
human CYP2C family.190 However, disrupting the ERE half site in the promoter region 
only partly restored the CYP2C19 transcription thus suggesting additional important 
ERE sites or other regulatory mechanisms by the activated estrogen receptor. ERα is 
known to affect other transcription factors by stabilizing their DNA binding but also by 
recruiting other co-activators to the transcription complex.191  
 
It was previously shown by Laine et al., that estradiol did not affect CYP2C19 enzyme 
activity in vitro,70 which is not only contradictory to our results but also to the studies 
suggesting that CYP2C19 metabolizes this specific estrogen.75 Even though the effect 
of EE on CYP2C19 activity needs to be confirmed in vivo, our data suggests that also 
hormone replacement therapy could impact the metabolism of other CYP2C19 
substrates. However, the transcriptional inhibition by ETE is observed at much lower 
concentrations than EE thus suggesting that OCs are more likely than HRT to cause 
important drug-interactions. 
This is the first study showing an effect of estrogens on CYP2C19 gene regulation and 
the transcriptional inhibition by ETE and EE was seen at much lower and more 
clinically relevant concentrations than for direct enzyme inhibition. We can conclude 
that transcription factor-mediated regulation is probably the major mechanism by which 
estrogens inhibit CYP2C19 activity.  
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4.2 │ Paper II - Decreased hippocampal volume and increased anxiety in a 
transgenic mouse model expressing the human CYP2C19 gene 
The human CYP2C19 gene displays high degree of polymorphism leading to absent, 
decreased or increased enzyme activity. This polymorphism has a great impact on drugs 
metabolized by CYP2C19 but has also been associated with depressive symptoms and 
personality traits.85,86,92 So far, no confirmed phenotype has been proposed for humans 
with regards to CYP2C19 enzyme activity besides the metabolic phenotypes described 
in the introduction. To elucidate the possible effects of high CYP2C19 expression, a 
transgenic mouse model expressing the human enzyme was investigated.  The study 
was performed with emphasis on brain development, behavior and characterization of 
the hippocampal formation. 
4.2.1 │ CYP2C19 and brain development  
 
4.2.1.1 │ Brain morphology at PND0 
 
The hippocampus 
Homozygous mice for the human CYP2C18/CYP2C19 locus displayed high neonatal 
lethality, thus suggesting that CYP2C19 might affect development. As a part of 
elucidating possible developmental effects of the genetic insert, brain morphology in 
CYP2C19Tg-Hom (n=4), CYP2C19Tg-Hem (n=5) and Wt (n=3) mice at PND0 was 
investigated. Upon visual assessment of brain morphology some rather striking 
abnormalities could be observed in the CYP2C19Tg-Hom brains. The hippocampal 
formation displayed an overall smaller appearance (about 60 %, Supplementary Figure 
2, paper II) with the different areas and layers appearing less developed as seen in 
Figure 5b-c (Figure 1, paper II). When comparing with a mouse brain developmental 
atlas, CYP2C19Tg-Hom hippocampi much resembles developmental stages E17-18.192 
This implicates that the hippocampal development is either terminated at this time-point 
or, perhaps more likely, that the development of the hippocampal formation is delayed 
in the transgenic mice. This was however not seen in hemizygous mice thus suggesting 
a gene-dose effect. 
  
Commissural agenesis 
The development of white matter structures are severely affected in CYP2C19Tg-Hom 
pups. Homozygous pups display total commissural agenesis, as seen in Figure 5a-b 
(Figure 1, paper II), involving the corpus callosum (CC), hippocampal commissure 
(HCC) and the anterior commissure (AC). These trajectories are the major connections 
between the cerebral hemispheres and the defects seen indicate a global defect in the 
midline crossing of commissural fibers.193,194 Such a delayed hippocampal development 
and total commissural agenesis do however not explain the premature death of these 
pups. However, induction of callosal agenesis in animal models often triggers agenesis 
in other major callosal tracts as well and this might also include deficits of the internal 
capsule that in many cases leads to perinatal death.195 The internal capsule has not been 
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investigated in the CYP2C19Tg-Hom mice but malformation of this capsule could 
however be the explanation for the early death of these mice. Callosal tract development 
is not the scope of this study since callosal defects are not observed in our visual 
assessment of the CYP2C19Tg-Hem brains at PND0. We can however not exclude the 
possibility of a callosal hypogenesis (partial agenesis) in the CYP2C19Tg-Hem mice 
although preliminary studies do not indicate this to be the case. Investigating 
commissural fiber thickness and density in adult CYP2C19Tg-Hem mice could be 
important for further understanding of the displayed adult phenotype. Complete or 
partial agenesis of the major commissures is one of the most commonly observed 
congenital malformations of the human brain,194 with agenesis of the CC occurring in 
approximately 1:4,000 live births.196 Commissural agenesis or reduced size and density 
have been associated to many syndromes and disorders,194 however mostly studied in 
autism spectrum disorders (ASD),193,196,197 MDD,198-200 and attention-deficit 
hyperactivity disorder (ADHD).193,201 
 
 
 
Figure 5 │ Brain morphology at PND0 in CYP2C19Tg-Hom pups and Wt controls. Images are 
cresyl violet stainings of Wt (n=3) and CYP2C19Tg-Hom (n=4) pups at PDN0. (a-c) The representative 
images display coronal sections from 3 rostral to caudal positions. (a-b) CYP2C19Tg-Hom mice display 
a distinct morphological phenotype with complete commissural agenesis. As pointed out by arrows on 
each image, the corpus callosum (top arrow a, and b), the hippocampal commissure (b) and the anterior 
commissure (bottom arrow a), are all essentially lacking axons crossing over the midline of the 
hemispheres. (b-c) The hippocampal formation in CYP2C19Tg-Hom pups much resembles 
developmental stages E17-18 thus suggesting a stalled or delayed development of this structure. Brain 
sections from CYP2C19Tg-Hem mice were indistinguishable from those of Wt litter mates. Figure from 
paper II. 
 
Since CYP2C19Tg-Hom pups only survive for a few days after birth, all adolescent and 
adult studies were performed on hemizygous mice. None of the above mentioned 
morphological changes were apparently seen in CYP2C19Tg-Hem pups; however a 
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more in depth evaluation of hippocampal size and commissural integrity at PND0 has 
not been performed.  
4.2.1.2 │ CYP2C19 is expressed during brain development in CYP2C19Tg-Hem 
mice 
As described above, severe morphological changes were found in the brains of PND0 
CYP2C19Tg-Hom pups. Further investigations on developmental effects were focused 
on CYP2C19Tg-Hem mice and expression of CYP2C18 and CYP2C19 was investigated 
during embryonic development, early postnatal days (gender unknown) and in 7-week-
old male mice. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 │ Expression of CYP2C19 and CYP2C18 mRNA in brain and liver tissue during 
embryonic development and early postnatal days. CYP2C18 and CYP2C19 mRNA expression pattern 
was investigated in liver and brain tissue during embryonic development (embryonic day 11 (E11), E14, 
and E18) and early postnatal days (postnatal day 0 (PND0) and PND7). The graph displays relative 
CYP2C18 and relative CYP2C19 mRNA expression levels in fetuses and pups of unknown gender. As 
evident from the graph, there is a brain specific expression of CYP2C19 mRNA that peaks at E18, with a 
6-fold higher brain expression compared to liver. The expression of the CYP2C18 gene was consistently 
low in both tissues and no expression of CYP2C18 or CYP2C19 mRNA was detected in Wt mice. Four to 
five mice were analyzed for each time-point and data are presented as mean with S.E.M. Figure from 
paper II. 
 
Little is known regarding the ontogeny of CYP2C18 in humans202 and CYP2C18 
protein has furthermore never been detected in either adult (26-31 weeks) 
CYP2C18/CYP2C19 transgenic mice172 or in adult human liver.36,203 CYP2C18 mRNA 
expression was however investigated during mouse development since the gene might 
display a specific developmental expression, like e.g. CYP3A7 in humans.204,205 
CYP2C18 mRNA levels were however found consistently low throughout the 
development in both liver and brain tissue, Figure 1, paper II. Expression analysis of 
CYP2C19 however, revealed relatively high mRNA levels in the brain at E14, E18 and 
PND0, with a peak value of more than 6-fold (E18) of that seen in liver as seen in 
Figure 6. It is rather difficult to compare mouse and human brain development. 
However, the E18 expression peak in mouse brain can roughly be translated to 
gestational week 15 in human brain development.206 Since the hippocampal formation 
seemed to be one of the most effected structures in the CYP2C19Tg-Hom pup, specific 
hippocampal CYP2C19 expression was investigated in four E18 CYP2C19Tg-Hem 
embryos. No significant differences were seen in expression between the four pooled 
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hippocampal samples and the cortex or the rest of the cerebrum indicating that the 
expression pattern is rather uniform in the developing brain (Supplementary Figure 1, 
paper II). Hepatic expression of CYP2C19 was constantly low during the embryonic, 
fetal and postnatal time-points investigated as clearly visualized in Figure 6. At 7 weeks 
of age a clear shift in hepatic and brain expression was observed, with silencing of the 
expression in brain tissue and a clear induction of hepatic expression (Figure 1b, paper 
II). This is in line with previously published expression data from adult CYP2C19Tg-
Hem mice with relatively low brain expression and high hepatic levels of CYP2C19 
mRNA.172 Mice have a large Cyp2c family of proteins, however no direct homologues 
to CYP2C18 and CYP2C19,178 thus making the observed human CYP2C19 expression 
specific for the transgenic mice. 
 
The ontogeny of CYP2C19 has been studied in human liver where expression is rather 
constant, and relatively high, throughout gestation. CYP2C19 expression levels range 
between 10-20 % of adult liver values.205,207 It is hypothesized that CYP2C19, and other 
CYPs with similar gestation expression patterns, might have important developmental 
roles that could be different from their functions in adult liver.204 This is interesting in 
correlation to our data even though the developmental expression pattern in liver is 
rather different between the species.  
4.2.1.2 │ Human brain expression of CYP2C19 
Expression of CYP2C19 during human brain development has never been investigated. 
As described above, it is however one of the highest expressed CYPs in the liver during 
human development thus suggesting that it might have important endogenous 
functions.205,207 In light of the embryonic expression pattern found in the transgenic 
mice, cerebral cortical brain samples from three different human fetal donors were 
investigated. CYP2C19 mRNA quantifications showed that CYP2C19 can be expressed 
at a level representing approximately 0.5 % of that found in human adult liver. Two 
different cerebral cortical samples of the donor from gestational week 24 displayed the 
highest CYP2C19 expression, showing approximately 0.3 and 0.6 % of the levels in 
adult human liver.  This was found in two separate regions and is interesting since it 
corresponds rather well to the expression peak at E18 in the transgenic mouse brain.206 
Samples were compared to adult liver expression were CYP2C19 is one of the most 
abundant CYPs and probably expressed in about 50 % of all hepatocytes. Therefore, 
CYP2C19 expression in the fetal samples could be rather significant especially since the 
expression most likely is localized to a specific region and even a specific cell type. 
  
It is of course important to remember that this is a pilot study with an exceptionally 
limited number of samples. However, studying human fetal samples are difficult since 
samples are extremely rare and therefore the results presented are important for future 
investigations of CYP2C19s possible endogenous role in human brain development. 
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4.2.2 │ CYP2C19s effects on behavior in the CYP2C19Tg-Hem mice 
 
4.2.2.1 │ Hyperactivity and stress sensitivity 
 
The open-field assessment and the tail-suspension test 
One major phenotypic characteristic observed in the CYP2C19Tg-Hem mice is that 
they display increased handling stress, i.e. they are more difficult to  move between 
cages and do not seem to respond as well to the handling before behavioral testing. As 
an initial step in the behavioral investigation of the CYP2C19 transgenic mouse model, 
transgenic mice and Wt controls were exposed to the open-field (OF) test. Many 
different aspects of behavior can be assessed in the OF and here we studied motor 
activity and anxiety-related behavior.166,167 Mice were exposed to the OF for 30 minutes 
where CYP2C19Tg-Hem mice displayed an increased locomotor activity, with an 
overall longer distance travelled during the session, compared to Wt litter mates at both 
ages investigated as seen in Figure 7a-b (Figure 5a-b, paper II). This suggests that the 
observed walking phenotype with extended elevation of hind paws, described in section 
3.2.1, does not affect their walking abilities. The hyperactive behavior was seen already 
at 7 weeks of age thus indicating that this phenotype is established early in life. 
 
Figure 7 │ CYP2C19Tg-Hem mice displayed increased reactivity to the open-field at both 7 and 15 
weeks of age. CYP2C19 transgenic mice and Wt controls were assessed in the open-field arena for 30 
minutes to investigate motor function. (a-b) CYP2C19Tg-Hem mice displayed increased motor activity 
during the first 15 minutes of the test when investigating distance travelled over time. This was true for 
both 7- and 15-week-old transgenic mice when compared to Wt controls. Data is presented as distance 
travelled over time in 5 minute bouts presented with mean ± S.E.M. The Student´s t-test was performed 
on each bout. * p<0.05 ** p<0.01 Figure adapted from paper II. 
 
For all rodents the open, highly illuminated arena is a potential threat and therefore 
stressful.158,159 Transgenic mice displayed an increased reactivity to the novel 
environment compared to Wt mice as seen in Figure 7a-b (Figure 5a-b, paper II). 
However, CYP2C19Tg-Hem mice were not hyperactive for the whole session period. 
They were habituating to the same activity levels as Wt mice after approximately 20 
minutes, which most likely corresponds to when the novelty stress decreases. Similar 
novelty-induced hyperactivity has been observed in for example bulbectomized rats.208 
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This hyperactive response differs from animal models of for example ADHD, where the 
hyperactivity usually starts when the environment gets familiar,209 and normally does 
not adapt to Wt values.210,211 The CYP2C19Tg-Hem mice display a low but significant 
hyperactive response in the OF and adapt to Wt values after approximately 20 minutes 
in the open-field suggesting that the hyperactivity is caused by novelty stress rather than 
by an ADHD phenotype. No difference in anxiety-like behavior was observed at any 
age when calculating exploration time in different parts of the arena. This aspect is 
further discussed in section 4.2.2.3.  
 
Figure 8 │ Immobility time in the tail-suspension test before (-Stress) and after Morris water maze 
training (+Stress). CYP2C19Tg-Hem mice and Wt controls were subjected to the TST and immobility 
time was manually calculated during the 6-minute session period. 15-week-old CYP2C19Tg-Hem mice 
(n=10) displayed 55 % less time immobility time compared to controls (n=6), here referred to as – Stress. 
A separate group of mice were subjected to the TST after the MWM, here referred to as a stressor 
(+Stress). Only Wt (n=10) mice were affected by this pre-exposure displaying reduced immobility, 
comparable with transgenic mice both with (n=8) and without prior stress exposure. ** p<0.01 *** 
p<0.001 Figure from paper II.  
             
Transgenic and Wt mice were also exposed to the TST to investigate any potential 
depression-like behavior. The TST is mostly used for its predictive validity of 
antidepressants and is one of the most commonly used tests in rodents for assessing new 
antidepressant drugs. Immobility time in the TST is generally considered as depression-
like behavior since most antidepressants reverse this phenotype.162 As seen in Figure 8 
(Figure 5c, paper II), 15-week-old CYP2C19Tg-Hem mice exposed to the TST 
displayed 55 % less immobility than Wt controls, thus not indicating a depressive 
phenotype. This behavior was not present in younger mice where no differences in 
immobility time could be observed. Reduced immobility time in the TST is most 
commonly interpreted as an antidepressant-like behavior, however, when phenotyping 
transgenic mice it is probably more appropriate to consider this response as increased 
stress-sensitivity.212-214 This interpretation is in line with the results from the OF 
suggesting an increased stress response in the CYP2C19 transgenic mice.  
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Acute restraint stress and plasma levels of corticosterone 
CYP2C19Tg-Hem mice display an increased reactivity to novelty and stressful 
situations as showed by the OF and TST assessments. This together with the apparent 
hippocampal phenotype we wanted to further investigate the stress sensitivity of the 
CYP2C19Tg-Hem mice. Corticosterone (CORT) is the major stress hormone in 
rodents215 and depletion or sustained high levels of CORT is known to affect 
morphology and survival of hippocampal neurons (reviewed by Hansson and Fuxe, 
2008).216 Even though the CYP2C19 transgenic mice displayed a more stress sensitive 
behavior in these tests including increased handling stress, when exposed to restraint 
stress, no differences were seen in CORT levels. CORT levels were almost identical in 
CYP2C19Tg-Hem mice and Wt littermates at both 7 and 15 weeks of age when 
assessed without stress, after 30 minutes of restraint stress, and after 30 minutes of 
stress plus a 30 minute recovery period, see Supplementary Figure 7, paper II. It could 
be hypothesized that these mice have the capacity to sustain a normal hormonal 
response to stressors when not exposed for a longer period of time, i.e. during the acute 
restraint stress. In the MWM CYP2C19Tg-Hem mice acquire a behavior similar to the 
floating/despair-behavior observed in the forced-swim test (FST).217,218 In the FST test, 
increased floating behavior is considered depressive-like, in the same way as 
immobility in the TST. Therefore it would be interesting to challenge the transgenic 
mice with a more chronic stress paradigm such as chronic mild stress, including cage 
tilt, over-night illumination etc. over a period of weeks or months.163 It could be 
hypothesized that CYP2C19 transgenic mice have difficulties coping with a more 
chronic stressor thus more easily developing a depressive phenotype. It would also be of 
value to further evaluate HPA-axis function and adaptation during chronic stress 
treatment.  
 
The initial objective of this study was to evaluate if the CYP2C19 transgenic mice 
displayed any depression-like behavior. Due to the early behavioral findings in the mice 
the project turned on a different track and focused more on trying to evaluate the 
displayed stress sensitivity and hippocampal phenotype. In retrospect it would have 
been interesting to evaluate a potential depressive phenotype in more detail. There are 
many tests that could have been performed and that might add important knowledge and 
insight into the phenotype observed in these mice. For example the sucrose-preference 
test investigates any anhedonia related phenotypes correlating to another 
endophenotypes of human depression.162  
 
4.2.2.2 │ Spatial learning and despair behavior in the CYP2C19Tg-Hem mice 
As an attempt to evaluate spatial learning abilities and hippocampal function adult 
CYP2C19Tg-Hem mice and Wt litter mates were trained and assessed in the Morris 
water maze (MWM), see Figure 9. Unexpectedly, CYP2C19Tg-Hem mice developed a 
rather distinct behavior over the 5 day training week. They displayed a gradually 
increasing floating or despair behavior that was not seen in the beginning of the training 
week, something that was furthermore not seen in the Wt controls at any day, see Figure 
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9b. However, three out of ten transgenic mice did not acquire this despair behavior and 
displayed similar or perhaps even better spatial memory during the retention test as 
clearly visualized in Figure 9c-d. However, since the number of individuals in the 
transgenic group for evaluation of the test got rather small it is difficult to draw any 
conclusions from the results, but they do however suggest that the CYP2C19Tg-Hem 
mice have normal learning abilities in the MWM.  
 
Figure 9 │ Spatial learning and hippocampal function was evaluated in the Morris water maze 
(MWM). (a) Experimental set-up of the MWM. 15-week old male mice were placed in a water pool 
divided into 4 quadrants named; northwest (NW), northeast (NE), southeast (SE), and southwest (SW). A 
transparent platform (10 cm) was placed in the NW quadrant with four visual cues placed around the 
pool, here represented by the star, moon, circle, and rectangle. MWM training sessions were performed 
with a hidden platform that was removed during the retention test. (b) Over the 5 day training period 
CYP2C19Tg-Hem mice gradually developed a floating or despair behavior in the water maze. (c-d) 
During the retention test learning and memory evaluation was performed by manually calculating number 
of platform crossings and total time spent in the platform quadrant (PFQ), during 60 s. All mice 
displaying more than 10 s of floating behavior were excluded. CYP2C19Tg-Hem mice do not differ in 
their ability to learn and navigate in the water maze as displayed by the number of platform crossings and 
time spent in the PFQ during the retention test. Data are presented as mean with S.E.M. * p<0.05 
 
Spatial navigation learning in the MWM is highly correlated to hippocampal 
neurogenesis in mice.184,185 Even though a drastic reduction of DCX positive cells can 
be seen in the DG of CYP2C19 transgenic mice (Figure 14) it does not seem to affect 
the learning abilities in the MWM. However, in correlation to the reduced hippocampal 
size, these behavioral data support our postulated hypothesis that the CYP2C19Tg-Hem 
mice display a specific size reduction of the caudal/ventral part of the hippocampus. 
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This part is thought to be more involved in the regulation of anxiety-like behavior but is 
not as related to learning abilities and memory function.113,115,116  
 
Rodents react differently to short- and long-term stress and when repeatedly exposed to 
a stressor the response can either stay the same, habituate (decrease), or increase.218-220 
The CYP2C19 transgenic mice display hyperactivity in the TST, an intense short term 
stressor and develop a despair behavior during MWM training, a relatively mild but 
long-lasting or repeated stressor. The reasons for these different responses remain to be 
elucidated but it could be hypothesized that the transgenic mice have difficulties in 
chronic stress coping. Another TST was performed on the MWM mice three days after 
the retention test to evaluate if this long term stress exposure also would affect their 
performance in this test. Interestingly, no effect was seen on the CYP2C19Tg-Hem 
mice that displayed a similar immobility time as seen previously, without the MWM 
stress; see paper II, Figure 5c. However, acquired despair behavior normally only stays 
for around 2-3 days, and thus could have vanished by the time they were tested in the 
TST. Wt mice however, significantly reduced their immobility time down to 
CYP2C19Tg-Hem levels. My interpretation of these differences in behavior is that the 
long term mild stressor, i.e. the MWM induced despair behavior in the transgenic mice, 
which either disappeared over three days resting or is not transferrable between tests. 
Wt mice on the other hand acquired an increased stress-sensitivity, comparable to 
transgenic behavior prior stress exposure.  
It might be of value to perform a more extensive evaluation of memory and learning 
ability in the CYP2C19Tg-Hem mice using other hippocampus-related tasks in addition 
to the MWM. Such a study could for example include Olton’s radial arm maze, which is 
furthermore also considered less stressful than the MWM.221 Although the MWM test 
did not address memory due to the unexpected behavior of the CYP2C19 transgenic 
mice, this response instead supports a disturbed affective phenotype. 
4.2.2.3 │ Anxiety-related behavior  
The LDB measures the conflict between rodent curiosity in exploring new environments 
and their fear of open, highly illuminated places. Spending less time in the light box is 
considered as increased anxiety-like behavior, mainly since anxiolytic drugs make 
rodents more prone to investigate the light environment.183,222 Fifteen-week-old 
CYP2C19Tg-Hem mice spent significantly less time in the light compartment thus 
suggesting a more anxious phenotype. In adult mice this behavior is significant with a 
reduction of time spent in the light compartment of 42 %, a similar trend was observed 
in 7-week-old mice as seen in Figure 10 (Figure 5d, paper II).  
 
Interestingly, the CYP2C19Tg-Hem mice do not display any anxiety-related behavior in 
the OF, where spending less time in the central part of the arena is interpreted as an 
anxious phenotype.167 However, results from the OF and LDB do not always overlap 
even though they are considered similar in their unconditioned avoidance of a potential 
threat. The differences seen are most probably due to the fact that there seems to be 
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some construct differences between these tests, i.e. that they are measuring different 
aspects of anxiety.223 
 
Other tests exploring similar aspects of anxiety-like behavior in rodents are available, 
such as the elevated-plus maze. Many anxiety-related animal models do display 
anxiety-related behaviors in at least two of these tests. It would therefore be interesting 
to investigate the CYP2C19Tg-Hem mice in the EPM for a more in depth evaluation of 
anxiety-related behavior in our model. 
 
Figure 10 │ CYP2C19Tg-Hem displayed 
anxiety-like behavior in the light-dark 
box at 15 weeks of age. During 5 minutes 
CYP2C19Tg-Hem and Wt mice were 
investigated in the light-dark box test. The 
time spent in the light and dark 
compartments was recorded and 15-week-
old CYP2C19Tg-Hem mice displayed 
significantly less time in the light 
compartment compared to Wt mice (n=15 
mice/group), thus indicating an anxiety-
like phenotype. At 7 weeks of age a similar 
trend was observed. ** p<0.01 Figure from 
paper II.  
 
All mice were also exposed to the SIH, mostly used for evaluating anxiolytic drugs. 
Anxiolytic drugs reduce the increase in body temperature seen after stress exposure,171 
very similar to the way the TST is used for evaluating antidepressant effects of drugs. 
However, no differences were seen in the increase in body temperature after stress. 
When subjected to the SIH test, both age groups and both genotypes responded with a 
similar stress-induced hyperthermia something that was not presented in paper II due to 
space limitations. As seen in Figure 11, a higher basal body temperature was however 
observed in CYP2C19Tg-Hem compared to Wt mice at both 7 and 15 weeks of age. 
This could be caused by different factors, including dysfunctional hypothalamic 
regulation.224 Whether the higher body temperature observed in CYP2C19Tg-Hem mice 
is caused by an increased psychological stress remains to be further investigated but it is 
an intriguing possibility in combination with the observed behavioral phenotype.  
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Figure 11 │Basal body 
temperatures of CYP2C19Tg-Hem 
mice and Wt controls. Rectal 
temperatures were measured and a 
significant increase in basal body 
temperatures was found between 
CYP2C19Tg-Hem mice and Wt 
controls at both 7 and 15 weeks of 
age. Data are presented as mean with 
S.E.M. *p<0.05 Figure from 
Supplementary Information, paper II. 
 
 
We have not investigated the effects of anxiolytic drugs on the behavior observed in the 
OF, LDB, and the SIH. However, we are planning to evaluate the anxiety-like behavior 
seen in the LDB by administrating anxiolytic drugs. This is an important aspect since a 
positive response of the anxiolytic drugs in the LDB would add predictive validity to 
our potential anxiety model.166 Regarding all three behavioral tests, LDB, OF, and TST, 
we observed that the behavioral phenotype in the CYP2C19Tg-Hem mice was more 
pronounced in young adult, 15-week old compared to adolescent, 7-week-old mice. So 
despite the plausible effect of CYP2C19 on brain development, the behavioral effects 
do not manifest until young adulthood, very much like MDD and other neuropsychiatric 
disorders in humans were the manifestation normally occurs at this age.93,225 
 
4.2.3 │ The hippocampal formation in CYP2C19Tg-Hem mice 
Due to the behavioral findings and the drastic developmental effects on hippocampal 
morphology much focus was spent on this important limbic structure throughout paper 
II. The hippocampus is mostly known for its important functions in learning and 
memory formation, stress regulation and emotional processing. 46, 110,226, 134  
4.2.3.1 │ Hippocampal size 
To investigate hippocampal volume or size in CYP2C19Tg-Hem mice two methods 
were used: area measurements of sections and MRI. Sections from both 7- and 15-week 
old mice were measured using cresyl violet stainings of 12 sections per mouse covering 
the whole hippocampal formation. A reduction in hippocampal size was seen in 
CYP2C19Tg-Hem mice at both 7 (12% reduction) and 15 weeks of age (11% 
reduction). Interestingly, the systematic sectioning revealed that this size reduction was 
not uniform throughout the structure but rather specific for the caudal-ventral part of the 
hippocampus as seen in Figure 12c-d (Figure 2b-c, paper II). Fifteen-week-old mice 
were furthermore also examined using a using a 9.4 T Varian MRI system to confirm 
the results from the measured sections. As clearly visualized in Figure 12 a-b these 
volumetric analyses revealed smaller whole brain (3.1 %) and hippocampal volumes 
(7.1 %) in CYP2C19Tg-Hem compared to Wt mice. Probably due to the low number of 
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animals investigated, no correlation was found between whole brain and hippocampal 
volumes. Hippocampal volumes were therefore not normalized against whole brain 
volumes. However, it is quite clear that the smaller hippocampal volume is due to a 
specific reduction of the caudal-ventral part as shown by sectioning analyses and does 
not affect the whole structure, see Figure 12c-d (Figure 2b-c, paper II). Many studies 
suggest that the hippocampal formation has distinct functions along its dorso-ventral 
axis, with the caudal-ventral part of the hippocampus being mostly involved in the 
regulation of stress response and emotional processing, in particular regulation of 
anxiety-related behavior in mice.116,118 This fits well with the behavioral phenotype 
observed in the CYP2C19 transgenic mice. That the hippocampus is found to be smaller 
already in young adolescent mice suggests that this might be a congenital effect, 
something that is further proven by the drastic changes seen in CYP2C19Tg-Hom mice 
at PND0. 
 
Figure 12 │ Smaller brain and hippocampal volumes in CYP2C19Tg-Hem mice. (a-b) Whole brain 
and hippocampal volumes were investigated in 15-week-old CYP2C19Tg-Hem mice and Wt controls 
(n=7/group) using a 9.4 T Varian magnetic resonance imaging system. Manual outlining using the 
software ITK-SNAP revealed smaller brain (3.1 %) and hippocampal volumes (7.1 %) in CYP2C19Tg-
Hem mice. (c-d) Hippocampal volumes were also estimated by systematic sectioning measuring the 
hippocampus in 12 coronal sections, covering most of the hippocampal formation. This clearly visualizes 
the specific reduction of the caudal-ventral part of the hippocampus in both 7- (c) and 15-week-old mice 
(d). Data are presented as mean with S.E.M. *p<0.05. HC, hippocampal. Figure from paper II. 
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4.2.3.1 │ The hippocampal formation, neurogenesis and stress coping 
 
Proliferation and DCX positive cells in the dentate gyrus 
In the DG of the hippocampal formation in mice, the neurogenesis process has been 
found to be critical for hippocampal function84, 85, 207,208 and reduced neurogenesis has 
been suggested as a possible explanation for reduced hippocampal volumes in 
depression and other psychiatric disorders. However, CYP2C19Tg-Hem mice do not 
display any differences in the classical proliferation markers, BrdU and Ki-67. Thus, no 
differences in proliferation rates were detected at either 7 or 15 weeks of age in the DG 
of transgenic mice.149,150 Furthermore, no differences in survival of BrdU positive cells 
in the DG where seen four weeks after BrdU injections in young mice as seen in Figure 
13. Total numbers were also corrected for hippocampal size (from MRI study) not 
changing the results, see Supplementary Figure 5, paper II.  
 
 
Figure 13 │ Investigation of proliferation rates and survival of newborn cells in the dentate gyrus 
of CYP2C19Tg-hem mice and Wt controls. (a) Number of proliferating cells in the dentate gyrus as 
measured by BrdU incorporation and Ki-67 expression at 7 weeks of age and Ki-67 at 15 weeks of age. 
No differences were detected between the genotypes. (b) CYP2C19Tg-Hem mice and controls were 
injected with BrdU and sacrificed 4 weeks later to investigate survival rates of newborn cells. No 
differences were seen in number of BrdU positive cells at this time point. (c) Representative images of 
proliferating cells in the dentate gyrus of Wt and CYP2C19Tg-Hem mice. Figure adapted from 
Supplementary Figure 4, paper II. Photo: A. Persson 
 
The neurogenesis process has been intensively studied in mice and displays a complex 
pattern with many different cell types and specific markers. As a part of the maturation 
process of new neurons in the DG, cells migrate in to the granule cell layer and are 
incorporated in the hippocampal circuits. This specific cell type is referred to as 
migrating immature neurons and can be visualized by the cytoskeleton marker DCX. As 
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seen in Figure 14 (Figure 4, paper II) adult CYP2C19Tg-Hem mice display a drastic 
decrease of the DCX expressing cell population in the DG, with a mean reduction of 42 
% compared to Wt controls. DCX is sometimes used as a proliferation marker but in the 
CYP2C19 mice a specific reduction of this marker is seen without any effects on 
proliferation. Knocked-out neurogenesis, leading to few DCX positive cells in the 
rodent DG, can lead to impaired negative feed-back on the HPA-axis.110 If this response 
is dependent on DCX cells is still not known but these cells do have specific properties, 
displaying increased excitability and are suggested to be important in hippocampal 
structural plasticity including axonal guidance and dendrite sprouting.143-145  As 
mentioned, we did not see any differences in corticosterone levels when exposing the 
transgenic mice to acute stress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 │ DCX positive cells are drastically reduced in the dentate gyrus of CYP2C19Tg-Hem 
mice compared to Wt controls. (a-b) Using immunohistochemistry immature neurons expressing DCX 
were visualized in the dentate gyrus of Wt and CYP2C19Tg-Hem (2C19Tg) mice.  CYP2C19Tg-Hem 
mice displayed a drastic reduction of immature neurons in the dentate gyrus of the hippocampal 
formation.  (c) Number of immature neurons is significantly reduced (42 %) in the hippocampal dentate 
gyrus of CYP2C19Tg-Hem mice. ***p<0.001 Figure from paper II. 
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If DCX cells are regulating the release of corticosterone, remaining cells are probably 
sufficient to respond and regulate the acute stress response. It would however be 
interesting to investigate how the response might be to a more chronic stressor. DCX 
positive cells are rather abundant in the DG, as seen in Figure 14 and hippocampal 
neurogenesis and DCX positive cells are most probably crucial for hippocampal 
mediated learning.114,151 However, despite the drastic reduction of DCX positive cells in 
the hippocampus of the CYP2C19 transgenic mice, spatial learning does not appear to 
be deficient in these mice. It could be possible that they have “enough” cells or that the 
cell population is in fact still inducible in the CYP2C19Tg-Hem mice when exposed to 
a learning task.  
It is difficult to draw any conclusions regarding behavior and the reduction of immature 
neurons seen in the hippocampi of CYP2C19 transgenic mice. It is however an 
intriguing discovery and this animal model could be used for further studies and 
understanding of this specific cell population. Nonetheless, it is rather clear that such a 
large reduction of this specific cell population would cause changes in hippocampal 
signal processing and overall function. Since the proliferation rate and the survival of 
proliferating cells are not affected in the transgenic mice it appears to be a specific 
reduction of immature neurons or possibly a defect in the neuronal maturation process 
in the DG. 
Inhibitory circuits in the hippocampus 
GABAergic interneurons are highly integrated in the hippocampal circuits and are 
important for overall signal processing in the DG. PA positive cells, one type of 
GABAergic interneurons, are abundant and critical for inhibitory signaling in the 
hippocampus.227 In the DG of 15-week-old CYP2C19Tg-Hem mice, a 22 % reduction 
was seen of PA positive cells compared to Wt mice as seen in Figure 4, paper II. 
However, no other difference in this cell population was detected within the CA regions 
of the hippocampus. The interneurons of the DG are highly integrated in the 
hippocampal circuits and it is still rather debatable whether all these cells are of 
developmental origin or if there is a possibility of adult-generated GABAergic 
interneurons in the hippocampus.228 This makes it difficult to speculate if the changes 
we observe in PA cell numbers are developmentally based or modulated in postnatal 
life. GABAergic interneurons are believed to aid the maturation process of new neurons 
both during development and in the adult hippocampus so reduced GABAergic input to 
progenitors within the DG might cause the lower numbers of DCX-cells.228 The reduced 
number of PA-positive cells in the DG could also influence overall hippocampal 
activity due to a reduced inhibition, and hyperactivity of the hippocampus has 
previously been associated with reduced GABAergic transmission.229 
One issue in counting cells in a structure that is smaller in the transgenic mice is that 
there might be a bias towards reduced number of cells due to the smaller volume. The 
differences in cell numbers were however seen in the DG, a part of the hippocampal 
structure that does not appear smaller. However, as a control for the smaller 
hippocampal size, corrections for hippocampal volume as measured by MRI was used 
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with no major changes for any of the IHC markers apart from PA positive cells in the 
DG that showed border-line significance after size correction (Supplementary Figure 5, 
paper II). 
 
Stress reactivity in the hippocampal formation of CYP2C19Tg-Hem mice 
Another aspect regarding the hippocampus in the CYP2C19 transgenic mice is the 
hippocampal response to stress. DCX and PA positive cells are involved in the 
hippocampal stress response in rodents and reduced levels of these cell populations 
have been implicated in increased stress sensitivity and hyperactivity of this particular 
brain structure.110,229 All mice were exposed to acute restraint stress and even though no 
differences could be seen in plasma levels of corticosterone between the genotypes, c-
fos mRNA levels were significantly higher after 60 minutes (30 min restraint stress + 30 
min recovery) in CYP2C19Tg-Hem mice. This pattern was seen at both 7 and 15 weeks 
of age (51 % and 46 %, respectively) as displayed in Figure 5e-f, paper II. There was 
however no differences in basal c-fos levels, but a steeper increase in levels can be seen 
already after 30 minutes of restraint stress. As mentioned previously, c-fos is 
extensively used as markers for neuronal activity230,231 and is induced by 
glucocorticoids through the glucocorticoid and mineralcorticoid receptors highly 
expressed in nearly all hippocampal neurons. The expression of c-fos is induced by 
different stressors, leading to increased mRNA and protein levels of c-Fos in the brain. 
The c-Fos protein dimerizes with members of the Jun family and forms the activator 
protein-1 (AP-1) complex, affecting the transcription of a wide variety of downstream 
genes.216 Thus, it is impossible to speculate what effects the observed increase in c-fos 
expression in the hippocampus would have on hippocampal function but we can 
conclude that in response to acute restraint stress CYP2C19Tg-Hem mice display 
increased neuronal activation in the hippocampus that is not directly correlating to 
corticosterone levels. Studies in adrenalectomized rats have previously shown that c-fos 
induction is not always dependent on corticosterone but the mechanism behind this 
response is still not clear.232 Since our study only measures c-fos mRNA levels in the 
hippocampus at three time points, with the latest measurement 60 minutes after 
initiation of the stressor, it is difficult to speculate if the increased mRNA expression is 
persistent for a longer period of time but could be interesting to investigate further.  
4.2.4 │ CYP2C19s endogenous function 
It is well known that CYP2C19 is an important enzyme in drug metabolism and the 
displayed genetic polymorphism is important to investigate due to its effects on drug 
plasma levels and treatment outcome. The main hypothesis behind this thesis is that the 
phenotype observed in the transgenic model is caused by the CYP2C19 dependent 
metabolism of endogenous substrates during brain development. Before starting this 
thesis work some studies were suggesting that CYP2C19 genetic polymorphism affect 
personality traits and depressive mood in humans.85,86,92 The study previously 
performed in our laboratory showed that loss of CYP2C19 activity was associated with 
less depressive symptoms.92  
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CYP2C19 is mainly a hepatic enzyme but here found in the developing fetal brain. 
Expression of CYP2C19 has to our knowledge never been investigated in human fetal 
brain and our preliminary human study indicates that this is the case. Thus, a role of 
CYP2C19 in the metabolism of endogenous substances during brain development 
seems to be a likely explanation for the phenotypes observed. The nature of the 
proposed endogenous substrates for CYP2C19 thus constitutes a critical point. Due to 
the broad substrate specificity of CYP2C19 it is almost impossible to predict substrates 
from merely studying their structure. Using recombinant CYP2C19 and the HEK293 
cell system described in this thesis we are however screening for potential endogenous 
substrates.  
CYP2C19 is suggested to be involved in the metabolism of several different 
polyunsaturated fatty acids including arachidonic and eicosapentaenoic acid.3,81 If 
developmental brain expression is confirmed in humans it is possible that a local 
metabolism of these fatty acids could affect brain development and maturation.233,234  
Most published data suggest that CYP2C19 is involved in the metabolism of steroid 
hormones including estrogens, progesterone, and testosterone.75,76,78 These steroids are 
known to be neuro-active and important both during brain development but also for 
postnatal brain maturation and plasticity.235-237 It is therefore possible that CYP2C19 
could be involved in the metabolism of such steroid hormones and that high or low 
expression of CYP2C19 causes changes in hormone levels that effect brain 
development and the susceptibility to develop anxiety disorders.  
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5 │ Conclusions 
This thesis can be concluded as follows: 
 The established HEK293 cell system, stably expressing the CYP2C19 enzyme, 
can be utilized for the effective and systematic investigation of CYP2C19-
specific endogenous substrates and inhibitors 
 17β-estradiol and 17α-ethinylestradiol display direct inhibitory effects on 
CYP2C19 enzymatic activity as shown by the above mentioned in vitro-system 
 Estrogens cause inhibition of CYP2C19 activity through transcriptional 
regulation at lower and more clinically relevant concentrations than required for 
direct enzyme inhibition suggesting transcriptional inhibition as the major 
mechanism of action of oral contraceptives on CYP2C19.  
 A novel estrogen-responsive element was discovered in the CYP2C19 promoter 
region. ER-α binds to this site and mediates transcriptional inhibition of the 
CYP2C19 gene. 
 CYP2C19 is expressed in the brain during embryonic development in the 
CYP2C19 transgenic mouse model. Our preliminary data suggests that this is 
also true for human brain development. 
 CYP2C19Tg-Hom mice display high neonatal lethality and severe brain 
malformations with complete commissural agenesis and delayed hippocampal 
development at post-natal day 0, further suggesting a developmental role for 
CYP2C19.   
 CYP2C19Tg-Hem mice lack an obvious neonatal phenotype but display 
increased stress sensitivity and anxiety-like behavior with the behavioral 
changes being more pronounced in adult compared to adolescent mice.  
 CYP2C19Tg-Hem adolescent and adult mice furthermore display a hippocampal 
phenotype, with reduced size, a drastic reduction of immature neurons, and fever 
GABAergic interneurons in the dentate gyrus of the hippocampus. Our data also 
suggests that the hippocampal formation is more stress-sensitive in 
CYP2C19Tg-Hem mice with neuronal hyperactivation, as measured by c-fos 
expression, after acute stress. 
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6 │ General summary and future perspectives 
Studies regarding CYP2C19 genetic polymorphism and related phenotypes have mostly 
been done with respect to its important function in drug metabolism. Besides displaying 
differential enzymatic activity with regards to this polymorphism, also drugs and other 
substances have shown to affect CYP2C19 activity. It is important to investigate factors 
that influence CYP2C19 function since this enzyme is involved it the metabolism of 
around 10 % of the drugs on the market today, and changes in enzymatic activity can 
lead to both lack of efficacy of drugs but also to serious side effects. Here we present 
evidence for a new transcription binding site in the CYP2C19 promoter responsive to 
estrogen receptor α. Through this new binding site estrogens used in oral contraceptives 
mostly 17α-ethinylestradiol, and hormone replacement therapy, mostly estradiol, inhibit 
transcription of the CYP2C19 gene thus causing a reduction in enzyme activity. Also a 
direct effect was seen by these estrogens on enzyme function but the transcriptional 
regulation was seen at much lower and more clinically relevant levels, thus suggesting 
that this is the most likely mechanism by which estrogens inhibit CYP2C19-mediated 
activity. This is important since oral contraceptives are one of the most commonly 
prescribed drugs for women and several in vivo studies have previously shown that 17α-
ethinylestradiol mediates an inhibition of CYP2C19 activity. Less is known regarding 
the in vivo effects of estradiol but our study suggests that it could be important to also 
investigate the effects of this estrogen of CYP2C19-mediated metabolism.  
The major part of this thesis has been dedicated to elucidate a possible CNS related 
endogenous function of the CYP2C19 enzyme. Human studies have suggested that 
CYP2C19 genetic polymorphism can predict personality traits and depressive mood. 
The characterized transgenic mouse model suggests that CYP2C19 might be involved in 
the metabolism of endogenous substrates involved in important developmental 
processes that affect brain development, leading to increased stress sensitivity and 
anxiety-like behavior later in life. It is still too early to suggest a potential substrate but 
by using recombinant CYP2C19 and the cell system described in this thesis, we are 
screening for endogenous substrates and are also investigating nirvanol-like structures 
as specific inhibitors of CYP2C19 activity. These inhibitors will soon be tested in vivo 
to explore if the phenotypic changes observed in the CYP2C19 transgenic mice can be 
reversed by these compounds. 
CYP2C19Tg-Hem mice display increased handling stress and display increased 
reactivity when exposed to novelty stress (OF) and a short term stressor (TST). Since 
the hippocampal formation is highly involved in stress reactivity and negative feed-back 
on the HPA-axis it is rather intriguing that we find this limbic structure so different in 
the CYP2C19 transgenic mice. CORT levels during and after acute stress does however 
implicate that HPA-axis regulation is functioning normally in the transgenic mice. Our 
hypothesis is that this might not be the case if the mice would be exposed to chronic 
stress paradigm or perhaps early-life stress, like maternal separation. We are planning to 
expose CYP2C19Tg-Hem mice to unpredictable chronic mild stress and investigate 
                                                                                       General summary and future perspectives                                                                                                                                                      
51 
 
HPA-axis reactivity and adaptation but also study the effects this might have on the 
behavior in e.g. the TST and LDB.   
Before studying the CYP2C19 mouse model any further it would be interesting to 
investigate CYP2C19 genetic polymorphism and distribution in different psychiatric 
cohorts to elucidate and confirm any associations. It would be interesting to look into 
MDD, anxiety disorders, and possibly also in combination with different stressful life 
events since increased stress reactivity is one of the major phenotypes seen in the 
transgenic mice. Mood and anxiety disorders are a major burden to the society today but 
still the pathophysiology behind these disorders is largely unknown and the 
pharmacotherapy available today is far from sufficient, with relatively low remission 
rates. Confirming associations between anxiety and other stress-related disorders and 
CYP2C19 genetic polymorphism could lead to increased understanding of the 
pathogenesis and pathophysiology of these disorders.  Use of the transgenic model in 
drug screening programs could potentially lead to new therapeutic agents.  
Animal models in psychiatric disorder have become valuable tools, mostly in the 
development and evaluation of new pharmacotherapies but also for investigating the 
pathogenesis and pathophysiology of these disorders. It is important to point out that the 
data presented in this thesis regarding this transgenic model has only been initially 
characterized phenotypically and for a stronger validity of this mouse model a link to a 
human phenotype needs to be confirmed. This would give this model more solid 
construct validity. Now the construct validity is based on the hypothesis that CYP2C19 
genetic polymorphism is associated to depressive mood and personality traits.  
It would be interesting to subject the animals to anxiolytic pharmacotherapy to 
investigate its construct validity, i.e. if anxiolytic treatment could reverse the anxiety-
like phenotype displayed in the light-dark box. However, this mouse model does display 
some face validity to endophenotypes displayed in both MDD and anxiety disorders. 
This includes displayed stress sensitivity on a behavioral level and a smaller and 
dysfunctional hippocampus. If the hippocampus is truly dysfunctional needs to be 
confirmed but this hypothesis is based on the observed reduction of several cell 
populations important for the plasticity and stress sensitivity of this limbic structure, and 
the increased neuronal activation after acute stress. I believe that already now this 
transgenic model can be used for studying processes affecting hippocampal plasticity 
and volume, both with regards to possible developmental effects but also 
pharmacotherapy. However, much more research needs to be done before this model 
can be considered a true model for anxiety and other stress-related disorders.
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7 │ Populärvetenskaplig sammanfattning 
Båda artiklarna i denna avhandling handlar om CYP2C19. CYP2C19 är ett protein som 
ingår i en stor familj av proteiner som heter cytokrom P450, så kallade CYP-proteiner. 
Dessa proteiner, som till största delen finns i levern, har till uppgift att hjälpa kroppen 
att ta hand om främmande ämnen som vi får i oss via luftvägar och föda. De har t.ex. en 
väldigt viktig roll i nedbrytning och utsöndring av läkemedel. Vissa CYP-proteiner har 
även kroppsegna funktioner som till exempel att reglera nivåer av hormoner i kroppen. 
Ett stort problem, vid t.ex. läkemedelsutveckling, är att nivåerna i kroppen av dessa 
proteiner skiljer sig väldigt mycket mellan olika människor. Dessa skillnader är till 
största delen genetiska, d.v.s. de beror på förändringar i våra gener vilket också gör dem 
ärftliga. För CYP2C19 kan individer ha allt från inget protein till normala nivåer men 
även extra mycket protein vilket gör att de läkemedel och andra ämnen som bryts ner av 
CYP2C19 kommer att variera i koncentration i kroppen beroende på hur mycket 
CYP2C19 man har. För vissa läkemedel kan det därför vara viktigt att först identifiera 
vilken gen-variant man har av CYP2C19 innan man väljer hur mycket patienten ska få 
av läkemedlet. För personer med låga nivåer av CYP2C19 kan annars en normal dos ge 
toxiska biverkningar och en person med höga nivåer kanske inte får någon effekt alls.  
CYP2C19 tar hand om mellan 6-10 % av alla läkemedel som finns på marknaden idag 
och det är därför viktigt att veta vad som påverkar hur mycket protein vi har i kroppen. 
För att ytterligare komplicera saken kan nivåerna av dessa CYP-proteiner även påverkas 
av andra ämnen och i synnerhet läkemedel. I artikel I studeras effekten av två olika 
kvinnliga könshormoner. Dessa hormoner används i stor utsträckning av kvinnor i form 
av preventivmedel men även i hormonbehandlingar efter klimakteriet. Då dessa 
behandlingar är så vanliga är det förstås viktigt att veta om de kan påverka nivåerna av 
andra läkemedel. Tidigare studier har visat att när läkemedel som bryts ner av 
CYP2C19 tas i kombination med dessa hormoner får vi högre nivåer av läkemedelen än 
normalt i kroppen. Det är dock fortfarande oklart hur den effekten uppkommer. Vi kan i 
denna studie visa hur dessa hormoner, via specifika mottagar-proteiner i cellerna direkt 
kan påverka genernas effektivitet. De hämmar nybildandet av CYP2C19 vilket gör att vi 
får lägre nivåer än normalt och läkemedlen kan inte brytas ner utan blir kvar i kroppen 
under en längre tid. Det är fortfarande inte helt klart hur stor effekt detta har men i 
framtiden kommer vi kanske behöva ta hänsyn till preventivmedel vid dosbestämning 
av vissa läkemedel. 
CYP2C19 bryter bland annat ner ämnen som har effekter på hjärnan som exempelvis 
antidepressiva läkemedel men även kroppsegna ämnen som hormoner. Dessa hormoner 
har visat sig ha effekter på hjärnan under fosterutvecklingen men även i vuxen ålder. 
Nyligen hittade vår forskargrupp att de personer som saknar CYP2C19 har ett mindre 
deprimerat grundtillstånd, jämfört med personer med normala nivåer. Det verkar alltså 
som att låga nivåer av proteinet skyddar mot depressiva symptom. Skulle det kunna vara 
så att höga nivåer ökar risken för depression? Depression och ångest är till stor del 
ärftligt och forskare har länge letat efter genetiska orsaker som skulle kunna förklara de 
stora skillnader som finns mellan individer när det gäller känslighet för dessa psykiska 
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sjukdomar. För att studera detta närmare har vi använt oss av så kallade transgena möss 
som fått den mänskliga CYP2C19-genen infogad i sin arvsmassa. I artikel II har vi 
studerat dessa möss och hittat att CYP2C19 finns i mössens hjärna under 
fosterutvecklingen. Detta är besynnerligt då CYP2C19 endast påvisats i lever hos 
människa. Ingen har dock studerat om detta protein finns i hjärnan under 
fosterutvecklingen och vi har i denna studie visat att det faktiskt verkar finnas där även 
hos människa. Vi har dock endast studerat tre olika mänskliga fosterhjärnor men dessa 
resultat är otroligt intressanta då hjärnan hos de transgena mössen visat sig utvecklas 
helt annorlunda mot normala möss. Detta tyder på att beroende på hur mycket 
CYP2C19 en person har kanske hjärnan utvecklas på olika sätt något som skulle kunna 
påverka hjärnans funktion i vuxen ålder. I vuxna möss har vi studerat beteende för att se 
om CYP2C19 kan ha en effekt som liknar psykisk sjukdom hos människa. Vi såg att 
dessa möss uppvisar en ökad stresskänslighet samt ett ångestliknande beteende. 
Patienter med depression har ofta ångestinslag och ökad stresskänslighet tros vara en av 
de viktigaste riskfaktorerna för att utveckla depression. Dessa observationer stämmer 
därför mycket väl överens med de preliminära studierna med minskade depressiva 
symptom hos individer som saknar CYP2C19. Vi kunde även se att dessa möss hade en 
mindre och mer stresskänslig hippocampus. Detta område i hjärnan är ofta mindre hos 
deprimerade patienter och är starkt kopplat till stresskänslighet men också kontroll av 
känslor. 
Vad vi hittat hos dessa möss kan bidra till kunskap om genetiska faktorer för utveckling 
av ångest och depression och de transgena mössen kan förhoppningsvis användas för att 
studera vilka mekanismer som kan orsaka uppkomsten av dessa sjukdomar. Mössen 
skulle även kunna användas för utveckling av nya ångestdämpande läkemedel. I nästa 
steg kommer vi nu studera CYP2C19 lite närmare under fosterutvecklingen mössen och 
i människa. Vi vill för försöka ta reda vilket eller vilka ämnen det kan vara som bryts 
ner av detta protein och som kan forma hjärnan till att bli mer känslig för utveckling av 
psykisk sjukdom i vuxen ålder. Dessa studier är otroligt viktiga då vi fortfarande vet 
väldigt lite om orsakerna till psykisk ohälsa hos människa och de läkemedel som finns 
tillgängliga idag är långt ifrån effektiva för alla som drabbas. 
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